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ABSTRACT

We previously demonstrated a regulatory role for intracellular Ca2+ ([Ca2+]i) in
human and murine adipocyte metabolism, with increased [Ca2+]i coordinately stimulating
lipogenesis and inhibiting lipolysis, thereby expanding adipocyte lipid mass. More
recently, we reported that la, 25-dihydroxyvitamin D3 [la, 25-(0H)i-D3 ] stimulates
adipocyte membrane vitamin D receptor (mVDR)-mediated Ca2+ influx, resulting in a
similar Ca2+-mediated modulation of adipocyte lipid metabolism. la, 25-(0H)i-D3 also
exerts an inhibitory effect on adipocyte uncoupling protein 2 (UCP2) mRNA and protein
levels via the nuclear vitamin D receptor (nVDR), independent of its effects on Ca2+
influx. Furthermore, we reported that suppressing la, 25-(0H)i -D3 levels by increasing
dietary calcium reduces adipocyte [Ca2+]i, stimulates lipolysis, inhibits lipogenesis,
increases thermogenesis, and consequently results in attenuation of adipocyte lipid
accretion and weight/fat gain during over-consumption and acceleration of weight/fat loss
during energy restriction. Notably, dairy sources of calcium exerted significantly greater
effects than calcium in the form of calcium carbonate, although the reason for this is not
yet clear. This thesis study was conducted to extend these observations by determining
the efficacy of a fermented dairy product, yogurt, presented either unflavored or
strawberry-flavored, compared to calcium carbonate, in accelerating weight/fat loss
secondary to caloric restriction in aP2-agouti transgenic mice. Mice were fed a low
calcium (0.4%)/high fat/high sucrose diet for 6 weeks in order to induce obesity. Mice
were then either maintained on the same low calcium basal diet ad lib or energyiv

restricted (70% of ad lib) on this diet either unsupplemented (basal) or supplemented
with calcium content increased to 1.2% either by replacing 34% of the protein with spray
dried plain or strawberry-flavored yogurt (with macronutrient adjustments) or by adding
calcium carbonate for 6 weeks. Adipocyte [Ca2+]i was only slightly decreased by energy
restriction alone but was further markedly reduced by all three high calcium diets (170±6
nM, n= lO vs. 60±5 nM, n=30, p<0.001). The three high calcium diets caused significant
stimulation of both basal and isoproterenol-stimulated lipolysis (78%-137%, p<0.05),
with yogurt exerting a significantly greater effect compared to calcium carbonate
(p<0.05). Similarly, the three high calcium diets suppressed adipocyte FAS mRNA by an
average of 87%. Body weight, as well as individual and total fat pad weights, reflected
these changes, with a 45% augmentation in fat loss on the two yogurt diets compared to
that on the low calcium diet secondary to caloric restriction (p<0.001). Calcium carbonate
supplementation produced an intermediate effect, with a lower 28% augmentation in fat
loss compared to that on the low calcium diet secondary to caloric restriction.
Furthermore, high calcium diets caused a higher core temperature and an increased white
adipose tissue UCP2 expression, indicating increased thermogenesis and decreased
metabolic efficiency. In conclusion, our data show that dietary calcium with calcium
sources from plain yogurt, strawberry-flavored yogurt and calcium carbonate supplement
suppress adipocyte [Ca2+]i and up-regulate UCP2 via suppression of la, 25-(0H)2-D3, and
thereby reduce energy storage, decrease metabolic efficiency and accelerate weight/ fat
loss during energy restriction, with significantly greater effects exerted by yogurt than by
V

supplemental calcium. Consistent with the animal observations, accumulating human
studies strongly support an anti-obesity role for dietary calcium. Therefore, dietary
calcium, especially dairy calcium, may be effective dietary regimen for the treatment of
obesity.
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INTRODUCTION

Obesity has reached epidemic proportions in the United States and is threatening to
become a global epidemic (1). Overeating and physical inactivity in combination with
genetic factors play the most important roles in the development of obesity (2). Since
obesity is strongly associated with an increased incidence of chronic diseases (3), weight
loss itself has been proven to be beneficial to reduce the morbidity and mortality risk
associated with obesity (4-6). Americans spend about $40 billion per year on weight-loss
treatments, mostly in the form of diets and dietary foods. And this approach seems to be
ineffective (7).
Since McCarron first noted a significant inverse relationship between dietary calcium
intake and body weight in his NHANES I data analysis in 1984 (8), accumulating body of
evidence strongly support the anti-obesity role of dietary calcium (9-22). However, it is
not until recently that the mechanism underlying this dietary calcium modulation of
adiposity is explored.
Previous studies of the mechanism of action of the agouti gene in obesity and insulin
resistance from our laboratory demonstrated a regulatory role for intracellular Ca2+
concentration ([Ca2+]i) in human and murine adipocyte lipid metabolism (23-26).
Increased adipocyte [Ca2+]i appears to promote expansion of adipocyte triglyceride stores
by exerting a coordinated stimulation of lipogenesis and inhibition of lipolysis.
Moreover, obesity in transgenic mice ubiquitously expressing agouti under the control of
the P-actin promoter was markedly attenuated by 4-week treatment of a Ca2+- channel
antagonist (nifedipine) (27).
2

More recently, we reported that la,25-(0H)2-D3 stimulates adipocyte Ca2+ influx via
the mVDR, resulting in a similar Ca2+-mediated modulation of adipocyte lipid
metabolism (13, 28). la, 25-(0H)2-D3 also exerts an inhibitory effect on adipocyte UCP2
mRNA and protein levels via the nVDR, independent of its effects on Ca2+ influx (29).
Furthermore, we reported that feeding high calcium diets (non-fat dry milk) results in
decreased adipocyte [Ca2ii, increased thermogenesis, and attenuation of adipocyte lipid
accretion and weight/fat gain in ad libitum fed mice and marked acceleration of
weight/fat loss secondary to caloric restriction (13, 16, 17). Accordingly, we proposed
that suppressing la,25-(0H)2-D3 levels by increasing dietary calcium would suppress
adipocyte [Ca21i, up-regulate UCP2, and consequently inhibit lipogenesis, stimulate
lipolysis, increase thermogenesis and decrease metabolic efficiency, thereby exerting an
anti-obesity effect.
Consistent with the animal observations, clinical and epidemiological observations
support these findings (13, 15, 21). Epidemiologically, the effect of calcium intake on fat
mass in humans was examined in the NHANES III data set (13). After controlling for
energy intake and energy expenditure, a strong inverse relationship was noted between
calcium intake and body fat in both women and men. The odds ratio of being in the
highest quartile of body fat was markedly reduced from 1.00 for the first quartile of
calcium intake to 0.75, 0.40, and 0.16 for the second, third, and fourth quartiles of
calcium intake, respectively.
Collectively, dietary calcium may exert its anti-obesity effect for humans through the
mechanism we proposed above, and further investigation is needed to confirm this.
Notably, dairy sources of calcium exerted substantially greater effects in acceleration of
3

weight/loss secondary to caloric restriction compared to the same levels of calcium in the
form of calcium carbonate supplement (13, 16, 17) although the additional component(s)
of dairy products responsible for this difference is not yet known. Moreover, the only
dairy product systematically tested in this manner has been non-fat dry milk (13, 16), and
it is not clear whether other forms of dairy products will exert comparable or greater
weight-loss effects secondary to caloric restriction. Accordingly, the objective of this
thesis research is to determine the efficacy of a fermented dairy product, yogurt,
presented either unflavored or strawberry-flavored, compared to calcium carbonate, in
acceleration of weight/fat loss secondary to caloric restriction in aP2-agouti transgenic
mice.
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LITERATURE REVIEW
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I. Obesity Epidemic

Obesity is a chronic disease involving genetic predisposition, environmental
influences and behavioral aspects and results in significant morbidity, reduced quality of
life, discrimination and early mortality (1). Obesity is objectively assessed by body mass
index (BMI), which is defined as weight of an individual in kg divided by height squared
in meters (kg/m2). Based on the facts that with increased degree of overweight and
obesity there is an increase in morbidity and mortality risk (2-4), the World Health
Organization (WHO) and the International Obesity Task Force (IOTF) recommended the
classifications of overweight and obesity as follows: overweight (BMI � 25.0); pre-obese
(BMI 25.0-29.9); class I obesity (BMI 30.0-34.9), class II obesity (BMI 35.0-39.9), and
class III obesity (BMI � 40) (5).
Obesity has reached epidemic proportions in the United States and is threatening to
become a global epidemic (6). Data from the latest NHANES conducted in 1999 and
2000 show that 64.5% of U.S. adults are now overweight, and 30.5% are obese compared
to only 14.5% in 1980 and 22.9% in NHANES III (1988-1994) (7). The prevalence of
overweight and obesity has risen dramatically over the past two decades, and the
increases are continuing. If this trend persists, the entire U.S. adult population could be
overweight or obese within a few generations (8). This alarming increase is also present
among the nation's youth: .......15% of U.S. children and adolescents are overweight (9).
Overweight that begins early in life persists into adulthood and increases the risk of
obesity-related conditions later in life (10). Furthermore, the prevalence has been
increasing in varying degrees, not only in the United States, but also in Britain and
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elsewhere in Europe, as well as in countries as diverse as Australia, Brazil, China,
Mauritius and Western Samoa (5).
Obesity represents a serious threat to health and quality of life because it is strongly
associated with an increased incidence of non-insulin-dependent (type II} diabetes
mellitus, coronary heart disease, hypertension, stroke, dyslipidemia, and several types of
cancer (1 1 ). Perhaps one of the most dramatic and disturbing findings in the past decade
was that of Pinhas-Hamiel et al. in 1996 (1 2). After analyzing 1027 patients aged 0- 19 y
who were diagnosed with diabetes in Cincinnati, they found a tremendous increase (from
4% to 33%) in the incidence of type II diabetes in children and adolescents between 1 982
and 1 994. In addition to family history and ethnicity (greater risk in African Americans),
overweight was identified as a major risk factor for type II diabetes. This study was
important because it showed that type II diabetes was not necessarily a slowly
progressing disease that affected adults but, in susceptible individuals, could be
manifested as early in life as adolescence, and it clearly emphasized overweight as
substantially more than a body weight issue in children. Other obesity comorbidities
include osteoarthritis and gout, gallbladder disease, and pulmonary diseases, including
sleep apnea (1 1 ). Obesity-related diseases cause more than 300,000 deaths annually in the
US alone (1 3).
The epidemic of obesity imposes a heavy burden on the healthcare systems of many
industrialized countries. Obesity-related morbidity may account for 6.8% of US health
care costs (1 4). The US Surgeon General' s Report estimates that the economic cost of
obesity in the United States was about $ 1 1 7 billion in 2000, including both direct medical
costs and indirect costs such as lost productivity.
10

Genetic factors appear to play an important role in the regulation of body weight and
body fat (1 5). However, the current epidemic of obesity appears to be caused largely by
an environment that promotes excessive food intake and discourages physical activity in
genetically susceptible individuals (16). Control of portion size, consumption of a diet
low in fat and energy density, and regular physical activity are behaviors that protect
against obesity, but it is becoming difficult to adopt and maintain these behaviors in the
current environment.
Obesity increases the risk of preventable death by 50% to 1 50% (17). Weight loss
itself is likely to be beneficial. Many studies have shown that during periods of weight
loss there is a uniform improvement in the profile of chronic disease risk factors (18, 19).
A moderate weight loss (So/()"' 1 0%) in people who were 50% to 1 00% overweight
produced significant drops in their blood pressure, blood levels of triglycerides, and
improved glucose tolerance as well. Moderate weight loss is also associated with
significant decreases in total cholesterol and increases in high-density lipoprotein (HDL)
cholesterol levels, and subsequently an improvement in the ratio of total cholesterol to
HDL cholesterol. In a large 12-yr prospective study of 43,457 overweight middle-aged
white women, those who intentionally lost weight and also had obesity-related health
problems had a 20% reduction in all-cause mortality (20). This was primarily due to a
40% to 50% decline in obesity-related cancers, such as those of the uterus and cervix, as
well as a 30% to 40% decrease in diabetes-associated mortality. In women with no
preexisting illness, intentional weight loss of �20 lb was associated with about a 25%
reduction in all-cause, cardiovascular, and cancer mortality.
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Methods for the treatment of obesity include dietary management, physical activity
and exercise, and antiobesity drugs, with gastrointestinal surgery being reserved for
extreme cases (1 1). Americans spend about $40 billion per year on weight-loss
treatments, mostly in the form of diets and dietary foods (17).

II. Etiology of Obesity
Obesity appears as a complex multi-factorial disease resulting from a prolonged
imbalance between energy intake and energy expenditure, especially in genetically
susceptible individuals (2 1 ). Available evidence suggests that obesity results from
multiple interactions between genes and environment. Parental obesity is the most
important risk factor for childhood overweight. Single gene defects leading to obesity
have been discovered in animals and, in some cases, confirmed in humans as congenital
leptin deficiency or congenital leptin receptor deficiency. However, in most cases, genes
involved in weight gain do not directly cause obesity, but instead increase the
susceptibility to fat gain in subjects exposed to an unfavorable environment such as
constant access to energy-dense food and minimal physical demands of daily living (22).

A. Genetic factors
There is strong evidence that genetic factors contribute to the development of obesity
in humans as well as laboratory animals. Twin, adoption, and family studies have now
established that an individual's risk of obesity is increased when he or she has relatives
who are obese. Other studies have shown consistently that -40 to 70% of the variation in
obesity-related phenotypes, such as BMI, sum of skinfold thickness, fat mass, and leptin
12

levels, is heritable (23). Human obesity is a polygenic trait, being determined by
interaction of several "susceptibility" genes, each of which may have relatively small
effects, with each other as well as with environmental factors such as nutrients and
physical activity (24).

1. Genetic influences on obesity in rodent models
The genes associated with several monogenic defects that produce obesity in
experimental rodents have been cloned and characterized. These genes and gene products
reveal novel molecular and biochemical mechanisms underlying the etiology of obesity
and provide promising targets for therapeutic intervention (25, 26). Several transgenic
and knockout rodent models that modify body fat provide insight into important systems
that are involved in the regulation of food intake, fat storage and/or energy expenditure
(26). The polygenic obese rodent models are excellent models to investigate the genetic
mechanisms underlying the development of human obesity involved in gene-gene and/or
gene-nutrient interactions (26).

a. Single gene defects
The major monogenic obese rodent models include obese (Lepobloi mouse, diabetes
(Leprdbldi mouse, Zucker fatty (Lep/alfa) rat, yellow obese (R/a) mouse, fat (Cp/0'1
Cp/0') mouse and tubby (tub/tub) mouse. Of these, the phenotype of the yellow obese
(AY/a) mouse is caused by autosomal dominant mutation while the rest are caused by
autosomal recessive mutations.

13

(1) The obese (Lep0b10°) mouse, diabetes (Lep,-dbld°) mouse and Zucker fatty (Lep,lalfa) rat
The phenotypic expression of the obese syndrome is similar across the three
autosomal recessive mutation models. These animals exhibit hyperphagia, morbid obesity
and type II diabetes, decreased energy expenditure, insulin resistance/hyperinsulinemia
and reproductive deficiency (27). The obese (Lep0b/0°) mouse and diabetes (Lep,-dbld°)
mouse are two most widely studied models as the result of Coleman's elegant series of
parabiosis experiments (28). Lepoblob mice whose peripheral circulation was joined
surgically with control mice exhibited normalization of body weight. This suggested that
Lepoblob mice were deficient in a circulating factor, now known as leptin or OB protein,
which regulated the size of the body fat depot. Alternatively, Lep,-dbldb mice, when linked
to their lean controls, did not exhibit weight loss, suggesting that Lep,-dbldb mice were
defective in the receptor for the circulating factor leptin.
The mouse ob gene, located on mouse chromosome 6, was cloned in 1994 (29). It
encodes leptin (OB), which contains 167 amino acids. In the obese (Lep0b10°) mouse, a
single base substitution at codon 105 was identified. This introduces a stop codon,
resulting in a premature-truncated inactive protein. The mouse db gene is located on
mouse chromosome 4 and encodes the leptin receptor (OB-R) (30-33). This receptor has
at least six alternatively spliced forms. OB-RL , the long form OB-R, has a long
cytoplasmic region containing several motifs required for leptin signal transduction, and
is expressed at high levels in hypothalamus. The other forms lack some or all of these
motifs. They are found at high levels in the choroids plexus, thus are speculated to play a
role in transporting leptin from the blood into cerebral spinal fluid (CSF), where it can
then move by diffusion to the brain centers that regulate body weight since leptin enters
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the brain by a specific and saturable transport mechanism (34). In Lep,-dbldb mice, a G�T
point mutation was identified in the genomic OB-R sequence, which generates a donor
splice site that converts a 106 nucleotide region with a premature stop codon into a novel
exon transcript (30). This abnormal splicing resulted in a short form OB-R without the
long intracellular domain. Thus, the long intracellular domain of OB-R is crucial for
initiating leptin signal transduction. A similar mutation is thought to be present in Zucker
fatty (Lep!alfa) rat (35, 36).
Leptin is produced primarily in white adipose tissue. Both peripheral and central
administration of recombinant leptin in Lepoblob mice lowered their body weight, percent
body fat, food intake, concentrations of glucose and insulin; increased metabolic rate,
body temperature, activity levels; and repaired reproductive function but had no effect on
Lep,-dbldb mice (3 7-40). Thus, leptin serves an endocrine function to regulate body fat
stores, and it can act directly on neuronal networks that control feeding and energy
balance. The hypothalamus is the primary target tissue which leptin act upon to exert its
energy-regulatory effects (41, 42). Hypothalamic neuropeptide Y (NPY) stimulates food
intake, decreases thermogenesis and increases plasma insulin and corticosterone levels.
Leptin has been shown to exert its weight reducing effects via inhibition ofNPY
synthesis and release (43). Thus, leptin responsive neurons in hypothalamus express
neuropeptides that are modulated by leptin and interact with each other in controlling
feeding behavior and energy balance.
The mouse ob gene is highly homologous with human, monkey and rat ob genes. In
contrary to the leptin deficiency found in the obese (Lep0b10") mouse, leptin gene
expression increases with body fat in a range of obese animal models, including the
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diabetes (Lep,-tlbld") mouse, the Zucker fatty (Lep,lalfa) rat, and rats fed a high-fat diet (44).
Several studies have examined leptin in a variety of obese and normal humans as well. A
generally positive correlation between fat mass and leptin levels is observed in
individuals with extreme obesity, suggesting that leptin deficiency is not a common cause
of obesity in human populations (45, 46). This has led to the suggestion that human
obesity may be caused by resistance to leptin action. As mentioned earlier, the transport
of leptin across the blood/brain barrier may be saturable, as leptin levels in human CSF
are normally <10% of serum levels (34, 47). Another possibility is that significant
numbers of humans will have a polymorphism in the OB-R gene, which results in the
production of receptors with different signaling potency (48). More likely, leptin
resistance may be a result of flaws within the signal-transducing pathway of the leptin
receptor, more analogous to the mechanism of insulin resistance (33).

(2) The yellow obese (AY/a) mouse
Dominant mutations in the mouse agouti gene confer a pleitropic syndrome
characterized by maturity-onset obesity, mild hyperphagia, decreased thermogenesis,
hyperinsulinemia, peripheral insulin resistance, impaired glucose tolerance, increased
linear growth and yellow fur (49, 50). The agouti gene, located on mouse chromosome 2,
was the first obesity gene cloned and characterized (5 1 , 52). It encodes a 1 3 1-amino-acid
protein with a consensus signal peptide. Agouti protein is normally transiently expressed
in the hair follicle during the mid-portion of the hair growth cycle. It acts to inhibit the
synthesis of eumelanin, a black pigment, by competitively antagonizing a-melanocyte
stimulating hormone (a-MSH) binding to its melanocortin- 1 receptor (MC 1 -R), resulting
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in a down-regulation of cAMP production and a temporary synthesis of phaeomelanin, a
yellow pigment. This produces the characteristic pigmentation pattern of wild-type mice,
a predominantly black hair shaft with a subapical yellow segment (53). In the yellow
mouse, dominant mutations in promoter regions result in ubiquitous expression of normal
agouti protein in a wide range of tissues, including white adipose tissue and
hypothalamus (51), throughout the life of the mouse. Transgenic mice ubiquitously
expressing agouti driven by the human P-actin promoter also develop yellow coat color
and become obese (54, 55), confirming that ectopic expression of normal agouti protein
in the obese yellow phenotype. Interestingly, the human homolog of the agouti gene,
named agouti signaling protein (ASIP) that is 85% homologous to mouse agouti, is
expressed primarily in adipose tissue and pancreas (56), suggesting that it may play a role
in human obesity.
Although the genetic defect in the agouti yellow mouse syndrome clearly involves
ectopic expression of the agouti gene, the actual mechanism of the yellow obese
syndrome is not clear. Both central and peripheral effects of agouti have been explored
extensively (57). Agouti is a potent antagonist of the melanocortin-4 receptor (MC4-R), a
related MSH-binding receptor MCl-R (58, 59). MC4-R is widely expressed throughout
the brain, with a high degree of expression in hypothalamus centers involved in appetite
and body weight regulation (60). Intracerebroventricular administration of a potent MC4R agonist inhibited food intake in four murine models of obesity and hyperphagia while
co-administration of the specific MC4-R antagonist completely blocked this inhibition
(61). Further, MC4-R knockout mice exhibit adult-onset obesity associated with
hyperphagia, hyperinsulinemia and insulin resistance, recapitulating many of the
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metabolic features of the yellow obese mouse (62). Thus, the chronic antagonism of
MC4-R may be responsible for the development of the yellow mouse obesity. An
accumulating body of evidence (63-70) indicates that peripheral actions of agouti are
likely to contribute to agouti-induced obesity as well, and strongly suggest a role of
agouti signaling in adipocytes and pancreatic J3-cells through its ability to increase
intracellular Ca2+ ([Ca2+]i) levels, and consequently stimulate triglyceride storage and
inhibit lipolysis, as discussed in detail later.
The yellow mouse exhibits maturity-onset obesity, which is primarily due to
increased metabolic efficiency, with a preferential partitioning of food energy into fat
storage (57). Yellow mice exhibit increases in the expression and activity of lipogenic
enzymes in both liver and adipose tissue ( 66, 71). Further, lipolysis is reduced in adipose
tissue of yellow mice compared to wild-type mice and the lipolytic response to
epinephrine is suppressed as well (72). Thus, the coordinated augmentation of
lipogenesis and inhibition of lipolysis observed in these mice may contribute to the
increase in metabolic efficiency. Given the role of insulin in promoting nutrient
partitioning into adipose tissue, hyperinsulinemia may contribute to the enhanced
metabolic efficiency of yellow mice (57). There is positive correlation between weight
gain and insulinemia and between insulin levels and lipogenic enzyme activity in obese
yellow mice (71). However, hyperinsulinemia is not sufficient to produce the obesity in
the absence of agouti expression. Transgenic mice expressing agouti at high levels in
adipose tissue under the control of the adipose tissue-specific fatty acid-binding protein
aP2 promoter (aP2-agouti transgenic mice) become obese if they are also
hyperinsulinemia while hyperinsulinemia was without effect in non-transgenic littermate
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controls (73).\ In fact, agouti and insulin appear to exhibit a synergistic interaction, which
results in the development of obesity (74, 75). Recent data indicate that these effects are
mediated by modulation of [Ca2+]i (63-70).

(3) The fat ( Cp/01/Cp/01) mouse
The fat mouse exhibits progressive adult-onset obesity and is characterized by
massive hyperinsulinemia (76). The apparent hyperinsulinemia was in fact a
hyperproinsulinemia (77). The fat gene, located on mouse chromosome 8, has been
shown to encode carboxypeptidase E (CPE), which is required for cleavage of two
arginine residues from the B chain of insulin during its processing from proinsulin. In
addition to proinsulin, a number of prohormones and proneuropeptides, including pro
opiomelanocortin (POMC), also require cleavage of paired dibasic residues from their C
terminal ends to yield the biologically active peptides. POMC is a precursor for peptides
such as adrenocorticotropic hormone (ACTH) and MSH, and MSH is known to act on the
melanocortin receptor family involved in the control of feeding (78). In the fat mouse, a
single base mutation that results in a serine to proline substitution at position 202 severely
reduces the amount and activity of CPE in both the pancreatic islet and pituitary (77). As
CPE is expressed in central nervous system (CNS), the obesity phenotype of fat mouse is
likely to result from defects in the production and activity of neuropeptides such as
POMC in hypothalamus (77-79).
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(4) The tubby (tub/tub) mouse
Homozygous mice with a mutation at the tub locus develop late-onset obesity and
insulin resistance (76, 80). The tubby gene, located on mouse chromosome 7, was cloned
in 1996 (80, 81). In tub/tub mouse, a single base mutation of G-+T within a splice donor
site in the 3' coding region abolishes the donor splice site and results in a larger transcript
containing the unspliced intron. The consequence of this mutation is the substitution of
the 44-carboxy-terminal amino acids with a 20-amino-acid sequence not found in the
wild-type protein. It was shown that tubby proteins localize to the plasma membrane by
binding phosphatidylinositol 4, 5-bisphosphate through its carboxyl terminal "tubby
domain", and function as membrane-bound transcription factors that translocate to the
nucleus in response to receptor-mediated activation of GTP-binding protein (G protein)
(82). The normal tubby proteins appear to be abundantly expressed in the hypothalamus,
suggesting that obesity in the tubby mice may stem from malfunction of signaling
pathways in the satiety center (81).

b. Transgenic and knockout rodent models of obesity
Table 1 lists several transgenic and knockout rodent models that have been shown to
modify body fat. Each of these transgenic animals provides some insights into important
systems that are physiologically perceived to be involved in the regulation of food intake,
fat stores and energy expenditure.
Available evidence indicates that the hypothalamic-pituitary-adrenal axis (HPA)
plays a key role in the control of energy balance in laboratory rodents (83). Transgenic
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Table 1. Transgenic and Knockout Rodent Models of Obesity
Gene

Agouti

Tg or KO•

Major tissues

Tg

CNS-, testis, heart,
adrenal gland

KO

CNS, liver

Tg

AT•

Tg

Ubiquitous

Tg

AT

KO

CNS

Recapitulated features
ofAY/a obese yellow mice

62

KO

CNS

Obesity, hyperphagia; adrenal
Insufficiency; altered pigmentation

92

BAT•

Obesity with hyperphagia; ablated BAT; 96
impaired BAT thermogenesis
101
Cold-sensitive but not obese

UCP I-DTA•
expression
KO
KO

AT, SM.,
immune system

Tg

normal rat
pancreatic islets
ZDF ra(
pancreatic islets

Tg

ucp3•

13-ARs ·

BAT

Phenotypes

References

Cushing' s syndrome

84

Impaired GCR function; obesity

85

Obesity due to adipocyte hyperplasia;
enhanced glucose disposal

91

Reproduced phenotype
ofAY/a obese yellow mice
Become obese if hyperinsulinemia

55

Not obese, not cold-sensitive;
macrophages generate more
ROS; resistant to infection
Impaired glucose-stimulated
insulin secretion
Enhanced insulin secretion

73

1 15
1 18
1 19

Hyperphagic but lean; increased
resting metabolic rate; improved
insulin sensitivity
Not obese; more coupled;
increased production of Ros·

107

AT

Modest obesity

132

AT

Massive obesity during overfeeding
due to failed DIT•

133

Tg

SM

KO

AT, SM

KO
KO

108

* Tg: transgenic; KO: knockout; CRH: corticotropin-releasing hormone; CNS: central nervous system;
GCR: glucocorticoid receptor; GLUT4: GLUT 4 glucose transporter; AT: adipose tissue; MC4-R:
melanocortin-4 receptor; POMC: pro-opiomelanocortin; UCP l-3 : uncoupling protein 1-3; OTA: diphtheria
toxin A-chain; BAT: brown adipose tissue; SM: skeletal muscle; ZDF rat: Zucker Diabetic Fatty rat; ROS:
reactive oxygen species; � 3-AR: � 3 -adrenergic receptor; �-ARs: � 1, �2 , �3 -adrenergic receptors; DIT: diet
induced thermogenesis
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mice overexpressing the corticotropin-releasing hormone (CRH) gene under control of
the metallothionein promoter exhibit endocrine abnormalities involving the HP A axis,
such as elevated plasma levels of ACTH and glucocorticoids (84). These animals display
features of Cushing's syndrome with truncal obesity, decreased linear growth, marked
bilateral hair loss, muscle wasting and reduced fertility.
The type II glucocorticoid receptor (GCR) is involved in glucocorticoid negative
feedback effects on the HPA axis activity. Barden et al (85) incorporated a type II GCR
antisense RNA construct into mice. The transgenic mice had greatly increased fat
deposition and, at -6 months of age, were twice the weight of normal mice. Northern blot
analysis of endogenous type II GCR mRNA indicates a maximal 50-70% decrease in
hypothalamus and cerebral cortex, and a smaller 30-55% decrease is seen in liver. The
transgenic mice also have a reduced GCR binding activity for glucocorticoids with raised
serum ACTH and glucocorticoids concentrations due to a failure of glucocorticoids to
inhibit HPA axis activity. Glucocorticoids can decrease the number of GCRs in both
hypothalamus and pituitary glands, and the high glucocorticoid levels in transgenic mice,
secondary to decreased type II GCR levels, could be an additional factor in
downregulating the type II GCR even further compared with antisense RNA (85). This is
consistent with previous studies emphasizing the dependence of all obesities on the
presence of adrenal glucocorticoids in a wide range of animal models, including the
genetically obese Lep/alfa rats, Lepoblob, Lep/bldb, and AY/a mice. Bilateral adrenalectomy
prevents, attenuates or reverses the development of obesity in these animals (86-89),
suggesting that glucocorticoids are required for the phenotypic expression of genetic
obesity.
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The GLUT 4 glucose transporter plays a pivotal role in insulin-stimulated glucose
transport in adipose tissue and muscle (90). Overexpression of GLUT 4 in white adipose
tissue (6-9-fold) and brown adipose tissue (3-5-fold) using the aP2 promoter/enhancer
increased total body lipid 2-3-fold (91). This was associated with a massive increase in
the basal transport of glucose into adipocytes and, interestingly, a twofold increase in fat
cell number, but no increase in fat cell size. This provided the first model of obesity
associated with hyperplastic growth of adipose tissue in the absence of cell hypertrophy.
Thus, it is a valuable model for understanding the mechanisms responsible for adipocyte
replication and/or differentiation in vivo.
Mice in which the POMC gene has been inactivated exhibit obesity and hyperphagia.
The mice also exhibit adrenal insufficiency owing to a lack of ACTH, and altered
pigmentation owing to a lack of MSH (92). The mice exhibit a phenotype that is
essentially identical to that observed in humans with inactivating mutations in the gene
encoding POMC (93). This model will undoubtedly prove useful in determining the roles
of the individual cleavage products of POMC on energy homeostasis.
Uncoupling protein-1 (UCPl) is a mitochondria proton transporter expressed
exclusively in mammalian brown adipose tissue (BAT). UCP 1 dissipates the proton
electrochemical gradient across the mitochondria membrane, thereby uncoupling
substrate oxidation from conversion of ADP to ATP, leading to generation of heat and
thus increased energy expenditure (94, 95). As BAT and UCPl are abundant in rodents,
BAT thermogenesis may be important in the regulation of energy expenditure in rodents.
Dysfunction of BAT could lead to decreased energy expenditure and could play a critical
role in the pathogenesis of obesity in rodents. Indeed, Lowell et. al created transgenic
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mice in which the UCP1 promoter drives BAT specific expression of diphtheria toxin A
chain (UCP-DTA), thus causing primary deficiency of BAT (96). In these transgenic
mice, both UCP1 content and BAT was markedly decreased. Correspondingly, BAT
thermogenic function was abolished in response to both cold and CL3l6,243, an
extremely selective �3-adrenergic receptor agonist. Moreover, these mice became obese
and developed hyperphagia, illustrating the possible link between BAT thermogenic
function, food intake and obesity in rodents. Interestingly, hyperphagia and obesity are
absent when UCP-DTA mice are reared at thermoneutrality, which indicates that even in
this model, there is no obesity without hyperphagia (97). Bray et al. demonstrated a
highly significant inverse relationship between spontaneous electrical activity of
sympathetic nerves innervating BAT and food intake in spontaneously feeding rats,
suggesting the reciprocal relation between BAT thermogenesis and food intake (98, 99).
Accordingly, Himms-Hagen proposed a thermoregulatory feeding hypothesis (100). That
is, the initiation of feeding occurs during an episode of increased sympathetic nervous
system activity that stimulates BAT thermogenesis and increases body temperature. Once
body temperature increases to a certain level, the feeding terminates. Thus, BAT
thermogenesis is important in control of meal size and satiety. When this function is lost,
the animal loses its ability to control meal size, and hyperphagia and obesity occur
subsequently.
Contrary to this thermoregulatory feeding hypothesis is another study conducted by
Enerback et al., demonstrating that mice lacking mitochondria UCPl are cold-sensitive
but not hyperphagia and obese (101). UCPl knockout (KO) mice were generated by
target inactivation of UCPl gene. The BAT of UCPl KO mice has enlarged lipid
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vacuoles but in all other respects it appears normal. The oxygen consumption after
treatment with CL316,243 was significantly blunted in UCP1 KO mice compared to
wild-type mice, like that found for UCP-DTA mice. UCPl KO mice are more cold
sensitive than UCP-DTA mice, indicating that their thermoregulation is defective. As it is
assumed that a role for BAT in energy balance is determined by UCP1-derived
thermogenesis, UCPl KO mice should be as, or more obese than, UCP-DTA mice.
Unexpectedly, the knockout of UCP1 caused neither hyperphagia nor obesity in mice fed
on either standard or a high-fat diet. To explain this unexpectancy, the investigators
proposed that an alternative mechanism for maintaining body mass must exist that cannot
protect against the cold. They found that UCP2, a recently discovered homologue of
UCPl, was up-regulated fivefold in the BAT of UCPl KO mice. Thus, UCP2 may
compensate for the loss of UCPl to maintain normal body mass without protecting
against cold.
Taken these studies together, UCP 1 is important for thermogenesis while BAT plays
a critical role in the regulation of energy balance in mice, and that BAT deficiency can
cause obesity.
UCP2 (102, 103) and UCP3 (104, 105) are more recently discovered members of the
mitochondria inner membrane transporter family with high homology (59% and 57%,
respectively) to the BAT-specific UCPl. UCP3 is expressed primarily in skeletal muscle
and BAT while UCP2 is widely expressed but at varying levels in a number of tissues
and cell types including skeletal muscle, BAT, WAT, brain, lung, heart, kidney, placenta,
spleen, leukocytes, macrophage etc. Both in vitro and in vivo studies support the
uncoupling activity of these proteins indicated by high proton leak and low mitochondria
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membrane potential (102, 103, 106-108). However, their physiological roles are
unknown. It is well established that BAT is an important tissue for thermogenesis in
rodents. However, in large mammals in which BAT is less common, skeletal muscle may
be more important for thermogenesis (109). Thus, based upon their high homology with
UCP-1 and their tissue distribution in skeletal muscle and adipose tissue, UCP2 and
UCP3 have been suggested to play important roles in regulating energy expenditure,
body weight and thermoregulation (102, 105). UCP2 and UCP3 are also implicated in the
regulation of lipids as fuel substrate in skeletal muscle on the basis that their mRNA
expressions are up-regulated during starvation (when fat stores are being rapidly
mobilized) and down-regulated during the early phase of re-feeding (when fat stores are
being rapidly replenished) (110, 111). These starvation/re-feeding studies suggest that
UCP2 and UCP3 may function as regulators of lipids as fuel substrate rather than as
mediators of regulatory thermogenesis. It has also been proposed that UCP2 and UCP3
could prevent the formation of oxygen-free radicals in skeletal muscle. Several studies
show that reactive oxygen species (ROS) production is a function of the mitochondria
membrane potential. It has been hypothesized that ROS are produced when the
mitochondria membrane potential is above a specific threshold. Mild uncoupling of the
mitochondria could be a mechanism to prevent the formation of ROS (112-114). This
mechanism could be important in skeletal muscle, given that it accounts for an important
fraction of the total oxygen consumption at rest and that this fraction is even higher when
skeletal muscle switches to maximal activity. Thus, one of the functions of UCP 2 and
UCP3 could be to prevent excessive oxidative stress in skeletal muscle (1 08). In
summary, the information available about the physiological role of UCP2 and UCP3 is
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still controversial and incomplete. To further illustrate the physiological function of these
two uncoupling proteins, both overexpression and knockout rodent models have been
generated.
Clapham et al. created transgenic mice that overexpress human UCP3 driven by a.
skeletal actin promoter in skeletal muscle (107). These mice are hyperphagic but weigh
less than their wild-type littermates. Magnetic resonance imaging shows a striking
reduction in adipose tissue mass. This phenotype is associated with increased resting
metabolic rate as measured by 25% to 40% higher resting oxygen consumption than the
wild-type littermates. The mice also exhibit lower fasting plasma glucose and insulin
levels and an increased glucose clearance rate, indicating improved insulin sensitivity.
This provides evidence that skeletal muscle UCP3 has the potential to influence
metabolic rate and glucose homeostasis in the whole animal, suggesting that
enhancement of UCP3 expression or stimulation of its activity is a promising approach
for the treatment of obesity.
Vidal-Puig et al generate UCP3 gene knockout (KO) mice using a gene targeting
approach (108). These mice do not develop obesity. They found that skeletal muscle
mitochondria lacking UCP3 are more coupled, indicating that UCP3 has uncoupling
activity. They also found that there is increased production of ROS in skeletal muscle
mitochondria lacking UCP3. They then demonstrate that UCP3, expressed at endogenous
levels, has uncoupling activity and its absence may lead to increased production of ROS,
consistent with the hypothesis that UCP3 may function to prevent excessive oxidative
stress in skeletal muscle. Their data also show that UCP3 does not seem to be required
for normal body weight regulation. This observation may not be completely surprising,
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since the genetic disruption of UCPl did not result in obesity (101). However, unlike
UCPl KO mice, mice lacking UCP3 are not cold sensitive, and they do not have up
regulation of either UCP2 or UCPl mRNAs. These suggest that UCP3 may not play an
important role in regulating body weight or adaptive thermogenesis in response to cold
exposure. However, it can not be excluded that the lack of UCP3 activity could be
compensated through post-translational activation of UCP2 and/or UCPl activity or,
alternatively, through activation of other unknown futile cycles. Thus double and triple
UCP KO mice would be useful tools to address these questions.
Similarly, Mice lacking UCP2 following targeted gene disruption are not obese and
have a normal response to cold exposure or high-fat diet (115). Moreover, they are
completely resistant to infection, in contrast with the lethality observed in wild-type
littermates. Macrophages from UCP2 KO mice generated more ROS than wild-type
mice, indicating a role for UCP2 in the limitation of ROS and macrophage mediated
immunity. Since there are high levels of UCP2 mRNA expression in organs of the
immune system such as spleen, lung and macrophages (102, 103), a role for UCP2 in
immunity or inflammatory responsiveness makes sense. The authors also found increase
of UCPl mRNA expression in WAT. Increase of UCP2 mRNA was previously noted in
BAT of mice deficient for UCPl (101). Thus, this study suggests that UCPl, but not
UCP2, may play a critical role in both cold- and diet-induced thennogenesis and
regulation of body weight. UCP2 may be important to limit ROS production by its mild
uncoupling activity. Between UCP2, immunity and ROS, UCP2 KO mice now provide a
new tool to further elucidate molecular mechanisms of resistance to infection.
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UCP2-overexpressing rats were used to understand the relationship between UCP2
and �-cell insulin secretion. As UCP2 rat homolog is present in pancreatic islets, among
other tissues (116, 117), two different groups created rats overexpressing UCP2 in
pancreatic islets. Chan et al. overexpressed human UCP2 in normal rat islets by infection
with an adenovirus (AdEGI-UCP-2) (118). The mice exhibited severe blunting of glucose
stimulated insulin secretion (GSIS), illustrating a direct, causal relationship between
overexpression of UCP2 and inhibition of GSIS in normal islets. The mechanism by
which UCP2 affects insulin secretion is predicted to be via decreasing cellular ATP
content. However, in another study conducted by Wang et al., UCP2 overexpression in
islets of Zucker Diabetic Fatty (ZDF) rat reduced �-cell ATP but increased the ATP/ADP
ratio and enhanced insulin secretion in ZDF rat islets (119). Thus, results to date in
normal and ZDF rats appear contradictary, but a possible mechanism for reduction of
GSIS during starvation and type II diabetes might include upregulation of UCP2
expression (120).
The sympathetic nervous system (SNS) influences many physiological functions
including body temperature homeostasis and lipid metabolism by releasing the
neurotransmitter norepinephrine that acts upon �-adrenergic receptors (�-ARs)(121). All
three known subtypes of �-ARs, namely � 1 -, �2- and � 3-AR, are expressed in both WAT
and BAT. They all couple via Ga-protein to adenylate cyclase (AC), leading to an
increase in cAMP. The resulting activation of protein kinase A (PK.A) mediates the major
actions of these receptors that include stimulation of lipolysis in white adipocytes and
thermogenesis in brown adipocytes (122).
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p3 -ARs are expressed predominantly in WAT and BAT in mice (123, 124).
Moreover, a number of in vivo studies have provided clues regarding the possible
physiological significance of P 3-ARs. In genetically obese Lep,Jalfa rats (124) and Lep0blob
mice (125), p 3 -ARs mRNA levels are significantly down-regulated, raising the possibility
that decreased p3 -ARs function might contribute to the development of obesity in these
animals. Selective activation of P 3 -ARs leads to marked increases in triglyceride
breakdown (lipolysis) and energy expenditure as measured by effects on oxygen
consumption, and long-term treatment of obese rodents with P 3 -selective agonists reduces
fat stores and improves obesity-induced insulin resistance (126-128). Of note, it has been
reported that a missense mutation of the human p 3 -ARs tends to be associated with
obesity, decreased energy expenditure, reduced insulin sensitivity and earlier onset of
type II diabetes (129-131). These observations suggest that P 3 -ARs might also play an
important role in humans as well. Thus, P 3-ARs represent one of a number of potential
anti-obesity drug targets (126-128). Susulic et al. generated P 3 -AR-knockout mice (P 3 KO) by direct injection of a DNA targeting construct into mouse zygotes ( 1 32). The (3 3 KO mice had normal body weight compared to wild-type mice, although they do exhibit
modestly increased fat stores (females more than males). Interestingly, fed insulin and
glucose levels and food intake are unchanged in the p 3 -KO mice, indicating that
compensatory mechanisms might operate in these animals to maintain normal energy
homeostasis. In fact, the expression of P 1 -AR mRNA is upregulated in WAT and BAT in
these animals. Finally, acute treatment of normal mice with CL316,243, a selective P 3 agonist, increased serum levels of free fatty acids (FFAs) (3 .2-fold) and insulin (14030

fold), increased energy expenditure (2-fold) and reduced food intake (by 45%). However,
these effects were completely absent in � 3 -KO mice, proving that the actions of CL are
mediated exclusively by � 3 -AR. Thus, this � 3 -KO mouse model should be useful as a
means to a better understanding of the physiology and phannacology of � 3 -ARs.
Recently, Bachman et al. created mice lacking all three �-ARs (�-less mice) and
provided direct evidence that the SNS and the �-AR signaling pathways are necessary for
diet-induced thermogenesis (DIT) (1 33). Previous overfeeding experiments indicated that
humans vary in their capacity to resist weight gain because of varying abilities to convert
food directly into heat, a process called DIT (1 34). Further, Landsberg et al.
demonstrated that SNS activity in a variety of tissues is boosted during overfeeding and
decreased during starvation (a state of energy conservation), suggesting the SNS as the
efferent system linking diet and thermogenesis (1 35). Bachman et al. showed that the �
less mice on a Chow diet had a reduced metabolic rate and were slightly obese. On a
high-fat diet (58% of kcal from fat), the �-less mice could not increase thermogenesis and
· became massively obese. In contrast, the wild-type mice are able to resist obesity during
overfeeding by activating DIT. Thus, �-less mice have a failure of DIT. In addition, the
(3-less mice are also intolerant to cold exposure, suggesting that the SNS-(3-AR pathway
control heat production in response to both diet and cold. BAT, because of its UCPl
mediated uncoupling of respiration and its intense sympathetic innervation, is thought to
be the source of DIT. Indeed, BAT in �-less mice was unresponsive to both physiological
(cold exposure) and phannacological (�-agonist) stimulation. Compared to wild-type
mice, BAT in �-less mice expressed lower levels of UCPl at room temperature and failed
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to induce UCPl expression after cold exposure. A maximally effective dose of
isopreterenol, a nonselective J3-agonist, stimulated oxygen consumption in wild-type
mice more than twofold but had no effect in J3-less mice. Thus, J3-ARs are necessary for
normal BAT function. Both supporting and opposing evidence exist regarding the role of
BAT in DIT. Transgenic mice in which UCPl promoter. drives BAT specific expression
of diphtheria toxin-A (UCPl-DTA), which have markedly ablated BAT, are obese and
sensitive to DIT (96). However, UCPl gene-knockout (UCPl KO) mice, although
showing greatly impaired cold-induced thermogenesis, are neither obese nor sensitive to
diet-induced obesity (101). Thus, UCPl is required for cold- but not diet-induced
thermogenesis whereas J3-ARs are required for both. In summary, the J3-less mouse model
indicates that J3-ARs are necessary for DIT and that the SNS-J3-AR pathway plays a
critical role in the body's defense against diet-induced obesity.

c. Polygenic models of obesity
The polygenic forms of obesity, which are normally of later onset and sometimes are
less severe, are often influenced by gene-gene and/or gene-diet interactions (44). The two
most studied polygenic mouse models are the AKR mouse model and the BSB mouse
model (26). Inbred mouse strains, produced by 20 or more generations of brother x sister
matings, provide the basic resource for analysis of multigenic traits (136). West et al.
developed and characterized a polygenic model of differential susceptibility to dietary
obesity in the inbred mouse strains (137). The AKR/J strain of inbred mouse becomes
significantly obese when fed a high-fat diet while the SWR/J strain remains relatively
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lean. Intercrosses between these two strains segregate the phenotype of sensitivity to
dietary obesity, thus provides a useful tool to pursue the metabolic and genetic basis of
this trait under the influence by gene-diet interaction. The BSB mouse model is derived
from C57BL/6J mice crossed with Mus spretus and the Fl mice subsequently
backcrossed onto the C57BL/6J strain (138). A significant percentage of the mice in the
backcross generation become obese spontaneously on a low-fat diet with a body fat
content that shows individual variation from 1% to 50% while neither of the parental
strains demonstrate spontaneous obesity, suggesting that obesity may result from the
interactions of two genes.
Quantitative trait loci (QTL) mapping is now a general technique to map all of the
genes underlying any complex trait such as obesity by using polymorphic genetic
markers covering the whole mouse genome (136). The QTL approach involves the
crossing of two strains that differ in the trait of interest to produce F2 or back-cross
progeny, individually phenotyping and genotyping each progeny for markers that are
spread throughout the genome. Then statistical association of markers and phenotypes are
performed to identify loci underlying the trait of interest (136). Warden et al. have
applied QTL mapping to spontaneous obesity in the BSB mouse model, with
identification of loci promoting obesity on chromosomes 6, 7, 12 and 15 (139, 140). West
et al. have also used QTL mapping to identify loci underlying diet-induced obesity in an
F2 cross between mouse strains SWR/J and AKR/J, with identification of loci linked to
adiposity on chromosomes 4, 9 and 15 (141, 142). So far, over 70 loci for polygenic
obesity have been identified from more than 15 different crosses (143).
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Since human obesity is polygenic, these polygenic animal models may be used to
investigate the genetic mechanisms underlying the development of human obesity
involved in gene-gene and/or gene-nutrient interactions.
2. Genetic influences on obesity in humans
There is strong evidence for a genetic component to human obesity. Studies have
shown that the prevalence of obesity is 2 to 8 times higher in families of obese
individuals than in the population at large, and that the familial risk increases with the
severity of obesity. Heritability estimates tend to be highest when derived from twin
studies (50% to 80%) while they are the lowest when derived from adoption studies (10%
to 30%) (144). Several studies have reported the presence of major gene effects for BMI,
body fat and abdominal visceral fat (24).
Monogenic obesity has been described in a few families due to mutations in leptin
(145, 146), leptin receptor (147), CPE (148), POMC (93), MC4-R (149-151),
prohormone convertase 1 (PCl) (152) or PPARy (153). For instance, two children with
homozygous mutations for loss of leptin function exhibit phenotypes of morbid obesity
and hyperphasia (145, 146). Another two children with loss of function mutations in
POMC gene exhibit impaired melanocortin signaling and display obesity and altered
pigmentation phenotypes (93). Finally, several groups have reported MC4-R mutations
(149-151). The metabolic phenotypes caused by MC4-R mutations in humans are similar
to those caused by impaired melanocortin signaling in mice. Although single gene
mutations as causes of obesity in humans is rare, these mutations confirm that these gene
products play a role in human obesity and may allow further elucidation of their signal
transduction pathways. Several groups have searched for linkage between obesity-related
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phenotypes and the chromosomal region encompassing leptin protein; a meta-analysis
suggests that there may be linkage with BMI (1 54).
The role of genetic factors in common human obesities is complex, being determined
by interaction of several susceptibility genes (polygenic), each contributing only small
fraction to the overall susceptibility to obesity, with each other and with environmental
factors such as diet and physical activity (24). This makes the search of human obesity
genes a very challenging task. Two strategies, the QTL mapping approach and the
candidate gene approach, are now used to identify human obesity genes (23 ).
The role of a genetic predisposition to obesity affects both energy intake and energy
expenditure. An update of the genetics of human obesity revealed that putative loci
affecting obesity-related phenotypes are found on all but chromosome Y of the human
chromosomes, and the numbers of genes and markers that have been linked with human
obesity are increasing rapidly and now approach 200 (155). Some genes are involved in
food intake control (NPY, leptin, POMC, cholecystokinin, melanin-concentrating
hormone etc.) or the regulation of energy expenditure and thermogenesis (�-2 and �-3
adrenergic receptors, UCP 1-3, leptin etc.), while the expression of some others influence
different signaling pathways, adipogenesis etc. (PPARy, aP2, PK.A, CCAAT-enhancer
binding protein etc.), affecting the energy balance (155).
The possible physiological mechanisms through which a genetic susceptibility may
be operating include low resting metabolic rate, low rates of oxidation, low fat-free mass
and altered food intake, as well as other factors related to macronutrient utilization,
energy expenditure or the hormonal profile, including insulin sensitivity (156). For
example, UCP2/UCP3 polymorphisms may produce variability in metabolic rates,
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thereby producing susceptibility or resistance to obesity (157, 158). Studies of 640
French Canadians and 790 Pima Indians showed that certain DNA sequences that flank
the UCP2 gene are found primarily in people with low metabolic rates .
With the publication of the Human Genome, it is likely that our understanding of the
genetic basis and the identification of novel genes involved in obesity will be greatly
improved. New pathways in the etiology of obesity will be uncovered, and in the more
distant future individual identification of genetic variants will be possible, making
individually targeted therapies available (159).

B. Environmental factors
On the simplest level, obesity can arise only when energy intake exceeds energy
expenditure. The primary environmental factors contributing toward constant positive
energy balance are high calorie intake and low levels of physical activity (160). Our
current environment is characterized by nearly unlimited supply of convenient, relatively
inexpensive, highly palatable, energy-dense foods, coupled with a lifestyle requiring only
low levels of physical activity for living. Such an environment promotes high-energy
intake and low energy expenditure (16). Egger & Swinbum described our present
westernized environment as an 'obesigenic environment' (161).
1. Diet
a. High-fat diets
In Westem societies, high consumption of dietary fat has been linked to a number of
adverse health outcomes, including cardiovascular disease, some forms of cancer and
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obesity (162). Considerable evidence from animal studies, carefully controlled laboratory
studies, cross-sectional studies, clinical trials and studies in individuals at high risk to
develop obesity clearly demonstrated that consumption of a high fat (HF) diet (�35% of
energy from fat) increases the likelihood of obesity and that the risk of obesity is low in
individuals consuming low fat (LF) diets (<20% of energy from fat) (163).
Obesity is rare in experimental animals maintained on a LF diet, even when they are
housed in small cages that limit physical activity. In contrast, providing sedentary
animals with ad /ibitum HF diets reliably produces increases in energy intake, increases
in efficiency of body fat gain, and obesity (164, 165). Dietary obesity can be reversed by
switching rodents from a HF to a LF diet, but the extent to which this occurs depends on
the severity and duration of the dietary obesity (166).
In numerous human studies, total energy intake was higher when subjects consumed
diets relatively high in fat than when they ate lower fat diets (167-169). Moreover, body
fat storage occurs at a greater rate when excess energy comes from fat than when it
comes from carbohydrate or protein (170). On the other hand, populations consuming
very-low-fat diets usually do not show high rates of obesity prevalence. A review of the
results from 28 clinical trials that studied the effects of a reduction in the amount of
energy from fat in the diet showed that a reduction of 10% in the proportion of energy
from fat was associated with a reduction in weight of 16 gld (171). This is consistent with
another behavioral study indicating that dietary restraint provides protection against the
obesity-promoting effect of the high-fat, high-energy density diet (172). Additional
support for the role of LF diets in regulating body weight comes from studies of formerly
obese individuals, a group considered to be at high risk for weight regain. After weight
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loss induced by an energy-restricted diet, weight regain at 2 yr was less in subjects
assigned to an ad libitum LF diet (5.4kg) than those consuming a fixed energy intake diet
(11.3kg) (173). Finally, subjects in the National Weight Control Registry, a database of
over 2000 individuals successfully maintaining a weight loss of at least 30 pounds for at
least 1 yr, report eating a diet low in fat and participating in very high levels of physical
activity (174).
Our current food supply is high in fat and HF diets promote obesity by increasing
energy intake, thus, increasing the probability of positive energy balance and weight gain.
However, the apparent effect of fat per se on energy intake in most studies is difficult to
separate from an effect of energy density. Since HF foods have a higher energy density
than LF foods, it is possible that the energy density of the diet rather than the dietary fat
was responsible for the increased energy intake (16). This hypothesis is supported by
several studies indicating that when the fat content but not the energy density of diets
varied, fat content did not affect energy intake (175, 176). Conversely, when energy
density was manipulated independent of fat content, energy density directly influenced
energy intake (177-179). Although there remains controversy over the effects of dietary
fat content on energy intake, considering the fact that not all energy-dense foods are high
in fat, few HF foods are low in energy density, reductions in dietary fat may still be the
most effective means of reducing the dietary energy density, and subsequently the
likelihood of excessive energy consumption (16).

38

b. Portion size
Accumulating evidence suggest that larger food portion sizes may contribute to the
increasing prevalence of overweight and obesity (16, 180, 181). Marketplace food
portions have increased in size and now exceed federal standards. Portion sizes began to
grow in the 1970s, rose sharply in the 1980s, and have continued in parallel with
increasing body weights (181). This growing trend toward larger portions is especially
evident in fast food restaurants where "supersizing" of menu items is commonplace (16),
and in buffet restaurants where people tend to consume larger portion sizes (180).

2. Physical activity
Three major components of energy expenditure that may influence body weight and
composition have been identified: basal metabolic rate (BMR), thermic effect of food and
energetic cost of physical activity (182). Thus, most available evidence suggests that low
levels of physical activity are associated with an increased risk of obesity (183). The First
National Health and Nutrition Examination Survey (NHANES I) carried out between
1971 and 1984 in 8300 individuals showed that low levels of physical activity in the
intervening 10-year period were associated with weight gains, and recreational activities
were inversely correlated with body weight (184).
Our current environment tends to discourage physical activity (16). Advances in
technology and transportation have reduced the need for physical activity in daily life.
The appeal of television, electronic games and computers has increased the time spent in
sedentary pursuits among children and adults. Facilitating this trend is the fact that most
children in the United States do not engage in daily physical activity at school.
39

Cross-sectional data have often found associations between leisure-time physical
activity (inverse) or total amount of time spent sitting down (direct) and BMI (182). Data
from the Seven Countries Study indicated that at the population level job-related physical
activity is an important determinant of subscapular skinfold thickness (185). In a sample
of 4063 children aged 8-16 y from NHANES III (1988-1994), boys and girls who
watched � 4h of television/d had the highest skinfold thicknesses and the highest BMis,
highlighting the importance of inactivity (as measured by television viewing) in the
etiology of overweight (186). Sedentary lifestyle or physical inactivity is accompanied by
a low fat oxidation rate in muscle and a low fat oxidation rate is a risk factor of fat gain or
fat re-gain after weight loss (22). Moreover, data from measuring total energy
expenditure in Mexican and USA Pima Indians support a significant role for physical
activity in the prevention of obesity in genetically susceptible populations (187). Finally,
prospective studies provide additional evidence to suggest that a population increase in
physical activity may help to prevent the growing prevalence of overweight and obesity
over time (188).

3. Interaction of diet and physical activity
Clinical data provide strong evidence that physical activity attenuates the effects of
HF diets on positive energy balance. Overall, energy balance was determined not by diet
or physical activity alone, but by the interaction between the two (16). Figure 1 shows the
hypothetical risk of developing obesity in individuals consuming a high-energy density
diet, for example, a typical Westem diet. These individuals can maintain a relatively low
risk of obesity by engaging in high levels of physical activity, by high dietary restraint, or
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Figure 1. Hypothetical risk of obesity in individuals consuming a diet high in energy density.
This risk can be modified by physical activity and by conscious limitation of total energy intake
(dietary restraint). As the energy density of the diet decreases, the risk of obesity (the height of all
of the bars) would be expected to decline (From Hill 1998, Science 280, 1371)

by a combination of moderate activity with some dietary restraint. For sedentary
individuals, a high level of dietary restraint or consumption of a diet low in energy
density is required to avoid positive energy balance.

III. Role of Intracellular Ca2+ ([Ca2+] 1) in Obesity

A. Unifying 'ionic hypothesis'
Obesity is closely related to other metabolic disorders, including insulin resistance/
hyperinsulinemia, hypertension and dyslipidemia, which are integrated into a metabolic
syndrome referred to as 'Syndrome X' (189), or the 'deadly quartet' (obesity,
hypertriglyceridemia, hypertension and insulin resistance/hyperinsulinemia) (190).
Considerable evidence suggests that these conditions are all characterized by an
underlying impairment in [Ca2+]i . Sustained elevations of [Ca2+]i have been observed in
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vascular smooth muscle cells, platelets, and erythrocytes in patients with hypertension
(191-195), skeletal muscle cells and adipocytes in patients with insulin resistance (196199), and cardiomyocytes in patients with left ventricular hypertrophy (195).
Correspondingly, Resnick proposed a unifying 'ionic hypothesis', in which a common
cell lesion underlying these disorders in different tissues was characterized, in part, by
elevations in steady-state [Ca2+]i levels (195). Consistent with this hypothesis,
antagonism of Ca2+ influx results in clinical improvements in blood pressure, insulin
resistance, platelet aggregation, and left ventricular hypertrophy (195). Draznin et al. first
reported that obese patients exhibited an elevation in basal adipocyte [Ca2+]i (196).
Further, studies of the mechanisms of agouti-induced obesity indicate that obesity may
also be partly a manifestation of a 'lesion' in [Ca2+]i regulation (63-70).

B. Agouti regulation of adipocyte [Ca2+Ji and lipid metabolism
Agouti was the first obesity gene cloned (51). In addition to the aforementioned
central effects of agouti via MC4-R antagonism, peripheral actions of agouti signaling in
adipocytes and pancreatic J3-cells may also contribute to agouti-induced obesity via
modulation of [Ca2+]i (57).
The carboxyl terminus of agouti protein not only retains full functional activity
relative to the intact protein in an in vitro assay system (200) but also exhibits a striking
structural homology in both number and spacing of cystein residues to the ro-conotoxins
and the plectoxins, two toxins produced by the cone snail Conus geographus and the
hunting spider Plecteurys tristis, respectively, that primarily target Ca2+ channels (63).
This homology between the carboxyl terminus of agouti and ro-conotoxins and the
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plectoxins suggests that agouti may act directly upon Ca2+ channels and thereby modify
channel activity.
Consistent with this, the obese AYla yellow mice exhibit increases in both Ca2+ influx
and steady-state [Ca2+]i in several tissues (64). This increase in [Ca2+]i was closely
correlated with both the degree of ectopic agouti expression and body weight, suggesting
the possibility of a causal mechanism between [Ca2+] i and obesity in these animals.
Further, recombinant murine and human agouti proteins caused dose-dependent increases
in Ca2+ influx and steady-state [Ca2+]i in a variety of cell types, including both murine
and human adipocytes (65). This action of agouti in increasing [Ca2+] i was inhibited by
Ca2+ channel antagonism (65) and mimicked by Ca2+ channel agonists (69).
Fatty acid synthase (FAS) is a multifunctional enzyme that is highly regulated by
nutrients and hormones and is rate-limiting in de novo lipogenesis (190). It has been
reported that FAS expression and activity are markedly increased in AY/a mice relative to
control mice (66), and that nanomolar concentrations of recombinant agouti protein
stimulate ""two-fold increases in FAS gene expression and activity and triglyceride
accumulation in 3T3-Ll adipocytes, as well as in human adipocytes, similar to the
maximal increases stimulated by insulin (66). This agouti modulation of FAS and
lipogenesis is dependent upon Ca2+ influx, as it can be mimicked in the absence of agouti
via Ca2+-channel activation and inhibited by Ca2+-channel antagonism (66-68).
Indeed, Ca2+-channel blockade has been shown to reduce body weight and fat pad
mass effectively in several animal models. Ca2+- channel antagonists, such as nifedipine,
verapamil and felodipine, caused decreases in body weight and fat pad mass in obese
SHHF/Mcc-facp rats (201, 202). Similarly, treatment of transgenic mice ubiquitously
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expressing agouti under the control of the P-actin promoter with a Ca2+- channel
antagonist (nifedipine) for 4 weeks resulted in significant decreases in adipocyte
lipogenesis and an 18% reduction in fat pad mass (203).
The human homologue of agouti, agouti signaling protein (ASIP), is expressed
primarily in adipose tissue (56). Previous studies from our laboratory demonstrated that
ASIP stimulated lipogenesis in both human and murine adipocytes via a Ca2+ -dependent
mechanism (66-68, 204). Moreover, ASIP expression was highly correlated with in vivo
FAS expression and activity in human adipose tissue (204). Thus, ASIP, a physiological
Ca2+ agonist, may play a role in human obesity, mimicking overexpression of agouti in
obese yellow mouse. Interestingly, a recent study involving 8 obese men and 14 obese
women showed that ASIP is not only associated with obesity but also gender specific
(205). BMI and ASIP gene expression were negatively correlated in men, whereas a
positive relationship was observed in women. Hip circumference was significantly higher
in women than men. Thus, the sexual dimorphism in the relationship between ASIP and
BMI may contribute to the recognized differences in parameters such as hip fat mass
distribution between men and women.
In addition to activating lipogenesis, increasing [Ca2+]i may also contribute to
increased triglyceride stores by inhibiting lipolysis. Adipose tissue from obese AY/a
yellow mice exhibited a 50% reduced basal lipolytic rate compared to wild-type
littermates (72, 206, 207). The response of this obese adipose tissue to epinephrine (72)
and p agonists (206, 207) was also lower than normal. Increasing Ca2+ influx with either
arginine vasopressin or epidermal growth factor was reported to inhibit lipolysis in rat
adipocytes in a Ca2+-dose responsive fashion (208). Further, agouti protein similarly
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inhibits both basal and agonist-stimulated lipolysis in human adipocytes via a Ca2+dependent mechanism. This inhibition can also be mimicked by Ca2+ channel agonists
and reversed by Ca2+ channel antagonists (69). The anti-lipolytic effect of [Ca2+] i is due
to a direct activation of adipocyte phosphodiesterase (PDE) 3B, resulting in a decrease in
cAMP and, consequently, reduced ability of agonists to stimulate phosphorylation and
activation of hormone-sensitive lipase (HSL) (209). Thus, agouti regulation of adipocyte
[Ca2+] i appears to promote triglyceride storage in human adipocytes by coordinately
stimulating lipogenesis and inhibiting lipolysis.
Finally, it is noteworthy that an agouti interaction with insulin is required for the full
expression of agouti-induced obesity since aP2-agouti transgenic mice become obese if
they are also hyperinsulinemic as a result of either exogenous insulin or a high sucrose
diet, while hyperinsulinemia was without effect on body weight in non-transgenic
littermate controls (73). Further, hyperplasia of J3-cells precedes the development of
obesity in AY/a yellow mice (210), suggesting that hyperinsulinemia may be a direct
effect of agouti acting on the pancreas. Since increased [Ca2+] i is a primary signal for
insulin release and agouti increases [ Ca2+] i in several cell types, agouti may stimulate
pancreatic Ca2+ influx and insulin release as well. Indeed, agouti is expressed and causes
a 5-fold increase in Ca2+ influx and a 2.2-fold increase in insulin release in human
pancreatic islets, as well as in J3-cell lines (70), suggesting a potential role for agouti in
the development ofhyperinsulinemia in humans and in obese AY/a yellow mice. This
hyperinsulinemia may act in an additive or synergistic manner with agouti-stimulated
adipocyte Ca2+ influx to increase adipocyte triglyceride accumulation (75). In fact, agouti
protein and insulin exert independent, additive effects on FAS transcription, with a 6-fold
45

increase resulting from their combination versus a 2-3-fold increase from each
+

independently (74). FAS responses to agouti are mediated by a distinct agouti/ Ca2

response sequence in the FAS promoter. This sequence maps to the -435 to -4 1 5 region
of the FAS promoter and is upstream of the insulin response element, which maps to -67
to -52, consistent with the observed additive effects of agouti and insulin on FAS gene
transcription (74). Based on these findings, since humans exhibit a similar pattern of
+

adipocyte agouti expression (56), similar agouti/insulin/ Ca2 interactions may result in
excessive adipocyte triglyceride storage.
Taken together, these data indicate that regulation of adipocyte [Ca2+]i, possibly
coupled with pancreatic [ Ca2+]i and insulin release, may be an important target for the
development of therapeutic strategies for the prevention and treatment of obesity, as
shown in Figure 2 (57).

C. l a, 25-(0H)2-D1 modulation of adipocyte [Ca2+Ji and energy metabolism
Several lines of evidence have suggested a role for l a, 25-(0H)2-D3, the biologically
active form of the vitamin D, in obesity. Circulating l a, 25-(0H)2 -D3 levels are elevated
in obese individuals (2 1 1 , 2 1 2). Vitamin D receptor (VDR) gene polymorphisms are
associated with susceptibility to obesity in patients with early onset type II diabetes (2 1 3).
Two single nucleotide polymorphisms (SNPs) in nuclear VDR (nVDR) gene intron 8 and
exon 9 account for a 9-kg body weight difference, or 4 kg/m2 . Moreover, human body
weight and BMI have been shown to be associated with a Bsml restriction site
polymorphism in nVDR gene (2 14). l a, 25-(0H)2-D3 induced hyperinsulinemia may also
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Figure 2. Agouti modulation of adiposity. Agouti stimulates Ca2+ influx in pancreatic J3-cells,
resulting in increased insulin release. Agouti stimulates Ca2+ influx in adipocytes, resulting in
increased fatty acid synthase (FAS) transcription and activity and inhibition of lipolysis. The
agouti-induced insulinemia augments the effects of agouti on adipocytes by independently
increasing FAS transcription and inhibiting lipolysis. (From Zemel 200 1 , CRC press)

contribute to the development of obesity, as la, 25-(0H)2-D3 stimulates insulin secretion
(215-217), and VDR gene polymorphism affects insulin secretion and susceptibility to
diabetes (218, 219). In vitro studies show that la, 25-(0H)2 -D3 modulates adipocytes
differentiation in several cell models (220-223). Moreover, la, 25-(0H)2-D3 promotes
the expression and secretion of lipoprotein lipase in cultured adipocytes (224), indicating
that 1a, 25-(0H)2-D3 may enhance adipocyte lipid accumulation by increasing fatty acid
uptake.
It has been previously shown that 1a, 25-(0H)i -D3 stimulates Ca2+ influx in a variety
of cells (217, 225-228), including vascular smooth muscle cells (227) and pancreatic J3cells (217) and to play a role in the development of hypertension and hyperinsulinemia,
respectively. This effect is rapid and mediated by a putative membrane vitamin D
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receptor (mVDR) rather than via the classical nVDR (226, 228). Baran et al. found the
plasma membrane-bound protein annexin II to exhibit specific and saturable binding for
la, 25-(0H)2-D3, and suggested that it may regulate the rapid effect of la, 25-(0H)2 -D3
on [Ca2+]i (229).
Recent data from our laboratory demonstrated that la, 25-(0H) 2-D3 also stimulates
Ca2+ influx in primary cultures of human adipocytes (230, 231), resulting in significant,
sustained dose-responsive increases in steady-state [Ca2+]i. Further, la, 25-(0H)2 -D3
caused 50%-100% increases in adipocyte FAS activity and mRNA expression, and an
80% inhibition of lipolysis stimulated by isoproterenol, a �-AR agonist (231). These
effects were mimicked by la, 25-(0H)i-lumisteroh, a specific agonist for mVDR, and
completely blocked by 1 �' 25-(0H)2-D3, a specific antagonist for mVDR (231 ). Thus,
1a., 25-(0H)2 -D3 modulates adipocyte Ca2+ signaling via nongenomic action and,
consequently, exerts a coordinated activation of FAS and inhibition of lipolysis, resulting
in an expansion of adipocyte triglyceride stores, similar to the action of agouti on
adipocytes. More recently, we reported that 1a, 25-(0H)2 -D3 exerted an inhibitory effect
on adipocyte UCP2 mRNA and protein levels (232), which may result in decreased
thermogenesis and subsequently increased metabolic efficiency. This effect is
independently of la, 25-(0H)i-D3-mediated Ca2+ influx and the mVDR, and is instead
mediated via the nVDR, indicating a novel role of nVDR in regulating adipocyte energy
metabolism.
In summary, la, 25-(0H)2 -D3-mediated both nongenomic action via Ca2+ signal
transduction in regulating adipocyte lipid metabolism and genomic action of inhibiting
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UCP2 expression via nVDR in regulating metabolic efficiency may represent a suitable
target for the development of pharmacological and/or nutritional intervention in obesity.

IV. Role of Dietary Calcium in Modulation of Adiposity

It is now well recognized that dietary calcium plays important roles in the
maintenance of bone mass, and in the regulation of hypertension, a major risk factor for
cardiovascular disease (233). McCarron, in his evaluation of the relationship between
blood pressure and nutrient intake in the U. S population in 1984, first predicted an
inverse relationship between dietary calcium and systolic blood pressure (234). Since
then, numerous well-controlled studies, especially the DASH (Dietary Approaches to
Stop Hypertension) randomized clinical trial, demonstrated that dietary calcium reduces
blood pressure (235-237). Notably, the heterogeneity in the blood pressure response to
increasing calcium intake was significantly less when dairy sources of calcium as
compared to calcium supplements were used in the studies (238). This protective effect of
dietary calcium can be explained in large part via suppression of calcitrophic hormones
[la.,25-(0H)2-D3 and/or parathyroid hormone (PTH)] by dietary calcium, thereby
normalizing [Ca2+]i in vascular smooth muscle cells since elevated [Ca2+]i increased
vascular smooth muscle tone, peripheral vascular resistance and blood pressure (239).
McCarron also noted a significant inverse relationship between calcium intake and body
weight in that same study in 1984 (234). Since then, accumulating animal and human
studies now suggest that dietary calcium not only reduces the risk of hypertension and
cardiovascular disease, but may play an important role in the prevention and treatment of
obesity as well, probably via modulating [Ca2+]i.
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.A.. .A.nitn.al studies
Metz et al. (240) and Bursey et al. (241) previously reported that increased dietary
calciUtn. reduced body weight and body fat cotn.position in spontaneously hypertensive
rats (Wistar-Kyoto rats and lean and obese Zucker rats). However, they were unable to
detn.onstrate the tn.echanistn. involved in this adiposity tn.odulation . .A.lthough sotn.e
investigators have attributed the effect of dietary calciUtn. on lipid tn.etabolistn. to
inhibition of dietary fat absorption or fecal fat loss, significant fecal energy loss does not
result frotn. tn.oderate increases in dietary calciUtn. (242-244).
Multiple studies have shown that increasing dietary calciUtn. suppressed 1a, 25(0H)2-D3 levels (195, 245). Moreover, la, 25-(0H)2 -D3 stitn.ulates Ca2+ influx in
adipocytes, thereby protn.otes triglyceride accUtn.ulation by coordinate stitn.ulation of
lipogenesis and inhibition of lipolysis (230, 231). Consequently, suppression of 1a, 25(0H)2 -D3 with high calciUtn. diets would be anticipated to reduce adipocyte [Ca2ii ,
stitn.ulate lipolysis, inhibit lipogenesis, thereby exerting an anti-obesity effect.
This concept was first confirmed in aP2-agouti transgenic tn.ice (transgenic tn.ice
expressing agouti in adipose tissue under the control of the aP2 protn.oter, sitn.ilar to the
hUtn.an pattern of expression) using non-fat dry tn.ilk (230). Mice were placed on a low
calciUtn. (0.4%)/high-fat/high-sucrose diet either unsuppletn.ented or with 25 or 50% of
the protein replaced by non-fat dry tn.ilk or suppletn.ented to 1.2% Ca with calciutn.
carbonate for 6 weeks. .A.t the end of the study, tn.ice on low calciUtn. (0.4%) diet
exhibited tn.arked increases in adipocyte lipogenesis, inhibited lipolysis, and accelerated
increases in body weight and adipose tissue tn.ass. However, all three high calciUtn.
(1.2%) diets reduced FAS expression and activity by 51% and stitn.ulated lipolysis 3 to 550

fold, resulting in 26 to 39% reductions in body weight and adipose tissue mass,
respectively. The magnitude of these effects depended upon the source of dietary
calcium, with dairy sources of calcium exerting significantly greater effects than calcium
carbonate. Thus, increasing dietary calcium modulates adipocyte lipid metabolism by
coordinatedly down-regulating lipogenesis and up-regulating lipolysis, and attenuates
diet-induced obesity risk.
A follow-up study was conducted to determine whether increasing dietary calcium
would accelerate fat loss secondary to caloric restriction following dietary induction of
obesity (246). Administration of the same low-calcium(0.4%)/high-fat/high-sucrose diet
to aP2-agouti transgenic mice for 6 weeks resulted in a ,..,,100% increase in adipocyte
[Ca2+]i and a corresponding weight gain of 29% and a 2-fold increase in total fat pad
mass, demonstrating that elevation of adipocyte [Ca2+]i is associated with increased
adiposity in aP2-agouti transgenic mice. The animals were then placed on energy
restriction (70% of an ad libitum fed control group) for an additional 6 weeks. Energy
restriction on the low calcium diet (0.4%) failed to reduce [Ca2+]i and only reduced body
weight and fat pad mass by 11% and 8%, respectively. In contrast, energy restriction in
conjunction with high calcium (1.2%) diets normalized [Ca2+]i and resulted in 19 to 29%
reductions in body weight and 42 to 69% decreases in fat pad mass depending on calcium
sources (elemental vs. dairy). Interestingly, the animals on the low calcium diets were
unable to increase adipocyte lipolysis or suppress lipogenesis despite being on an energy
restricted regimen. In contrast, the high calcium diets caused marked reductions in FAS
expression and activity (35 to 81%), 2 to 3-fold increases in lipolysis during energy
restriction. In addition, ad lib feeding of the basal low-calcium diet caused sustained
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hyperinsulinemia in the aP2-agouti transgenic mice. Energy restriction per se reduced the
plasma insulin levels, but increasing dietary calcium did not further reduce insulin levels
but nonetheless exerted potent effects on body weight and fat pad mass reduction. This
indicates that the effects of dietary calcium on attenuating weight gain and accelerating
weight loss are not due to insulin suppression and instead are likely to result from the
observed suppression of adipocyte [Ca2+]i by suppressing la, 25-(0H)2-D3 and
subsequent modulation of adipocyte lipid metabolism. Notably, dairy calcium (non-fat
dry milk) exerts approximately twice the effect of the calcium supplement on both
adipocyte lipid metabolism and on body fat and body weight despite that all three high
calcium diets exerted comparable effects in lowering [Ca2+]i. This finding suggests that
other components of dairy may act via a Ca2+-independent system to further reduce
adiposity.
In this study, it was also found that mice fed high calcium diets exhibited higher core
temperature (0.48 to 0.67°C) and increased expression of white adipose tissue UCP2.
UCP2 has been shown to stimulate mitochondrial proton leak and therefore play a
potential role in thermogenesis, metabolic efficiency and obesity (102, 103). Core
temperature is an indirect metabolic index associated with thermogenesis. In fact, an
increased core temperature was observed in another study in transgenic mice ubiquitously
expressing agouti under the control of the �-actin promoter after mice were treated with
Ca2+ channel antagonist nifedipine (203). The contribution of thermogenesis to anti
obesity action of Ca2+ channel blockade has been addressed in previous studies (247,
248). However, this mechanism remains controversial in that some investigators have
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attributed the thermogenic effect of Ca2+ channel blockade to the increased function of
BAT. This study of dietary calcium modulation of adiposity suggests that up-regulation
of UCP2 expression may be responsible for the increased thermogenesis. This concept
has been confirmed by our recent study demonstrating that la, 25-(0H)i -D3 exerted an
inhibitory effect on adipocyte UCP2 mRNA and protein levels via the nVDR,
independent of its effects on Ca2+ influx via the mVDR (232). Thus, suppression of la,
25-(0H)i -D3 with high calcium diets and consequent up-regulation of UCP2 via a
genomic action may contribute to our observations of increased thermogenesis in mice
fed with high calcium diets. This effect, coupled with decreased lipogenesis and
increased lipolysis secondary to decreased [Ca2+]i mediated by nongenomic action may
contribute to an anti-obesity effect of dietary calcium as shown in Figure 3 (233).

Ca2+
@•
• ------- I,25-(0H)2-D
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Figure 3. Mechanisms of the anti-obesity effect of dietary calcium (From Zemel 2002, J. Am.
Coll. Nutr. 2 1 , 146S)
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This concept of dietary calcium modulation of adiposity was further extended in aP2
agouti-transgenic mice by using a calcium-fortified breakfast cereal as a calcium source
to increase dietary calcium from 0.4% to 1.2% (249). The effects of the high calcium
cereal were similar to those described above for calcium carbonate, producing significant
attenuation of diet-induced obesity and acceleration of weight/fat loss during caloric
restriction. Interestingly, the addition of a small amount of non-fat dry milk, sufficient to
increase dietary calcium from 1.2% to 1.3% (with dietary macronutrients held constant)
doubled the rate of fat loss. Thus, dairy sources of calcium exert a greater anti-obesity
effect than calcium carbonate. Although the additional factor(s) in dairy responsible for
this effect have not yet been identified, milk is recognized as a rich source of bioactive
compounds (250), which may act independently or synergistically with the calcium to
attenuate lipogenesis, accelerate lipolysis and/or affect nutrient partitioning between
adipose tissue and skeletal muscle. Notably, milk proteins have been reported to contain
significant angiotensin-1 converting enzyme (ACE) inhibitory activity (251, 252). The
ACE hydrolyses largely inactive decapeptide angiotensin I to octapeptide angiotensin Il
(All), which increases blood pressure (252). In addition to its synthesis in the classical
rennin angiotensin system, the hypertensive hormone All is secreted from adipose tissue
as well (253, 254). Moreover, All exerts an insulin-like effect in adipocytes and acts as a
lipogenic hormone to increase FAS enzyme activity and mRNA content, subsequently
increasing fatty acid and triglyceride synthesis (255). Indeed, inhibition of the rennin
angiotensin system mildly attenuates obesity in rodents, and limited clinical observations
support this concept in hypertensive patients treated with ACE inhibitors (256).

54

Collectively, the primary effect of dietary calcium appears to be inhibition of 1 a,25(0H)2-D3 effects on energy storage and utilization. Adipocyte Ca2+ signaling is an
attractive target for the development of obesity interventions (57, 233, 239).

B. Human studies
Since McCarron first noted a significant inverse relationship between calcium intake
and body weight in his evaluation of the relationship between blood pressure and nutrient
intake in the U. S population in 1984 (234), several lines of evidence from human studies
have supported this relationship although the mechanism was not explored at that time.
Data from the Nationwide Food Consumption Survey (1 987-88) demonstrated that
individuals with the lowest calcium intakes tended to have the highest body weights.
Moreover, African-Americans consume the lowest level of calcium and exhibit the
greatest prevalence of obesity (257). During the course of a clinical trial investigating the
antihypertensive effect of calcium in obese African-Americans, it was noted that 1 2
months of yogurt supplementation, sufficient to raise daily calcium intake from
approximately 400 to 1000 mg/day, resulted in a 4.9 kg reduction in body fat in obese
African-Americans without an accompanying reduction in caloric intake (230).
A randomized clinical trial demonstrated a markedly greater weight loss (7.0 vs. 1 .7
kg) in patients maintained on a milk-based diet for 1 6 wk, compared with those
maintained on conventional hypocaloric diet at the same level of energy intake (258).
Although this difference was attributed to the novelty of the milk-based diet possibly
contributing to a greater level of compliance, our data suggest that this effect may also be
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attributed to suppression of l a.,25-(0H)2-D3 and adipocyte [Ca2+]i by dairy calcium, with
a consequent reduction in the efficiency of energy utilization.
Recently, accumulating human studies strongly support the anti-obesity effect of
dietary calcium. In a two-year prospective study of 54 normal weight young women aged
1 8 to 3 1 years participating in an exercise intervention (259), subjects with high calcium
intake, corrected by total energy intake, gained less body weight and body fat than those
with low calcium intake. Moreover, increased total calcium and dairy calcium intakes
predicted fat mass reductions independently of caloric intake for women at lower energy
intakes (below the mean of 1 ,876 kcal/d). In Phase 2 of the Quebec Family Study, adults
between 20 and 65 years of age (23 5 men and 23 5 women) were divided into three
groups according to their daily calcium intake as follows: group A<600mg, group B
between 600 and 1000 mg and group C> 1000mg. It was found that a low daily calcium
intake is associated with an increase in body fat, particularly in women (260).
Davis et al. (26 1) have conducted a series of calcium intervention studies designed
with the bone mass the original outcome variable, and have recently re-evaluated these
data with body weight and body fat the outcome variable. The re-analysis involved 780
women who participated in five clinical trials (i.e., four observational and one double
blind, placebo-controlled randomized trial). Analysis reveals a consistent negative
associations between calcium intake and body weight for all age groups (3rd, 5th and 8th
decades of life), and an odds ratio for being overweight of 2.25 for young women in the
lower half versus the upper half of calcium intake. Data from the randomized controlled
trial demonstrated a calcium treatment effect of 0.325 kg weight loss per year over four
years with no intentional change in caloric intake; overall, the relationships derived from
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this re-analysis indicate that a calcium intake increase of 1000 mg/day is associated with
an 8 kg reduction in body weight.
A similar beneficial effect of dietary calcium on body fat mass accumulation has been
demonstrated in growing children as well. In one short-term study (262), 50 healthy non
obese children with low calcium intakes (<800mg daily) aged 2.5 to 8.8 years were
studied for 6 months. The children were randomly divided into a dairy or control group.
The dairy group was supplemented to 1200 mg calcium or 4 servings of dairy foods
daily. Control children ingested their usual diet with calcium intake less than 800 mg
daily. At the end of 6 months, children from the dairy group gained less body fat than
those from the control group. Similarly, in another five-year longitudinal study of
preschool children (263), higher mean longitudinal calcium intakes and more
servings/day of dairy products were associated with lower body fat.
To extend those findings of dietary calcium modulation of adiposity in aP2-agouti
transgenic mice to humans, we recently conducted a clinical trial involving 32 obese
adults (264). They were maintained for 24 weeks on balanced 500 kcal/day deficit diets
and randomized to control group (400-500mg Ca/day), high calcium group (control diet
supplemented with 800 mg Ca/day), or high dairy group (3-4 servings of low-fat dairy
products/day, total Ca intake of 1200-1300 mg/day). At the end of the study period,
patients from the control group lost only 6.4% of their body weight while those from the
high calcium group and high dairy group lost 26% and 70% more, respectively. Fat loss
followed a similar trend, with the high calcium and high dairy diets augmenting the fat
loss found on the low calcium diet by 38% and 64%, respectively. Moreover, fat loss
from the trunk region represented 19% of total fat loss on the low calcium diet, and high
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calcium and high dairy diets increased this number to 50% and 66%, respectively. Thus,
increasing dietary calcium significantly augments weight and fat loss secondary to caloric
restriction and increases the percentage of fat lost from the trunk region. Moreover, dairy
products exert a substantially greater effect on both fat loss and fat distribution compared
to an equivalent amount of supplemental calcium.
Finally, at the population level, a role for dietary calcium in modulating body
composition was assessed via analysis of the third National Health and Nutrition
Examination Survey (NHANES III) (230). After controlling for energy intake, age,
race/ethnicity and activity level, the odds ratio of being in the highest quartile of percent
body fat was reduced from 1 .0 for the first quartile of calcium intake to 0. 75, 0.40 and
0. 1 6 for the second, third and fourth quartiles of calcium intake, respectively, for women;
a similar inverse relationship was also noted in men. These data indicate that for any
given level of energy intake and expenditure, a low calcium diet favors increased adipose
tissue energy storage while a higher calcium diet favors increased energy utilization.
In summary, laboratory, clinical and population data all support a significant anti
obesity effect of dietary calcium, and dairy sources of calcium seem to exert greater
effects than calcium supplement. Therefore, dietary calcium could be an effective
regimen for the prevention and treatment of obesity at the population �evel.
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PART 3
DIETARY CALCIUM AND YOGURT ACCELERATE BODY WEIGHT AND
FAT LOSS SECONDARY TO CALORIC RESTRICTION IN aP2-AGOUTI
TRANSGENIC MICE

83

I. Abstract
We previously demonstrated a regulatory role for intracellular Ca2+ ([Ca2+] i) in
human and murine adipocyte metabolism, with increased [Ca2+] i coordinately stimulating
lipogenesis and inhibiting lipolysis, thereby expanding adipocyte lipid mass. More
recently, we reported that la., 25-dihydroxyvitamin D3 [ la., 25-(0H)i-D3 ] stimulates
adipocyte membrane vitamin D receptor (mVDR)-mediated Ca2+ influx, resulting in a
similar Ca2+-mediated modulation of adipocyte lipid metabolism. la., 25-(0H)2-D3 also
exerts an inhibitory effect on adipocyte uncoupling protein 2 (UCP2) mRNA and protein
levels via the nuclear vitamin D receptor (nVDR), independent of its effects on Ca2+
influx. Furthermore, we reported that suppressing la., 25-(0H)i-D3 levels by increasing
dietary calcium reduces adipocyte [Ca2+]i, stimulates lipolysis, inhibits lipogenesis,
increases thermogenesis, and consequently results in attenuation of adipocyte lipid
accretion and weight/fat gain during over-consumption and acceleration of weight/fat loss
during energy restriction. Notably, dairy sources of calcium exerted significantly greater
effects than calcium in the form of calcium carbonate, although the reason for this is not
yet clear. The present study was conducted to extend these observations by determining
the efficacy of a fermented dairy product, yogurt, presented either unflavored or
strawberry-flavored, compared to calcium carbonate, in accelerating weight/fat loss in
aP2-agouti transgenic mice secondary to caloric restriction. Mice were fed a low calcium
(0.4%)/high fat/high sucrose diet for 6 weeks, resulting in a 17% increase in body weight.
Mice were then either maintained on the same low calcium basal diet ad lib or energy
restricted (70% of ad lib) on this diet either unsupplemented (basal) or supplemented
with calcium content increased to 1.2% either by replacing 34% of the protein with spray
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dried plain or strawberry-flavored yogurt (with macronutrient adjustments) or by adding
calcium carbonate for 6 weeks. Adipocyte [Ca2+]i was only slightly decreased by energy
restriction alone but was further markedly reduced by all three high calcium diets (170±6
nM, n= lO vs. 60±5 nM, n=30, p<0.001). The three high calcium diets caused significant
stimulation of both basal and isoproterenol-stimulated lipolysis (78%-137%, p<0.05),
with yogurt exerting a significantly greater effect compared to calcium carbonate
(p<0.05). Similarly, the three high calcium diets suppressed adipocyte FAS mRNA by an
average of 87%. Body weight, as well as individual and total fat pad weights, reflected
these changes, with a 45% augmentation in fat loss on the two yogurt diets compared to
that on the low calcium diet secondary to caloric restriction (p<0.001). Calcium carbonate
supplementation produced an intermediate effect, with a lower 28% augmentation in fat
loss compared to that on the low calcium diet secondary to caloric restriction (p<0.001).
Furthermore, high calcium diets caused a higher core temperature and an increased white
adipose tissue UCP2 expression, indicating increased thermogenesis and decreased
metabolic efficiency. In conclusion, dietary calcium with calcium sources from plain
yogurt, strawberry-flavored yogurt and calcium carbonate supplement suppress adipocyte
[Ca2+] i and up-regulate UCP2 via suppression of lcx,25-(0H)2-D3 , and thereby reduce
energy storage, decrease metabolic efficiency and accelerate weight/fat loss during
energy restriction, with significantly greater effects exerted by yogurt than by
supplemental calcium.
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II. Introduction

Since McCarron first noted a significant inverse relationship between dietary calcium
intake and body weight in his NHANES I data analysis in 1984 (1), accumulating body of
evidence strongly support the anti-obesity role of dietary calcium (2-15). However, it is
not until recently that the mechanism underlying this dietary calcium modulation of
adiposity is explored.
Previous studies of the mechanism of action of the agouti gene in obesity and insulin
resistance from our laboratory demonstrated a regulatory role for intracellular Ca2+
([Ca2+]i) in human and murine adipocyte lipid metabolism (16-19). Increased adipocyte
[Ca 2Ji appears to pro�ote expansion of adipocyte triglyceride stores by exerting a
coordinated stimulation of lipogenesis and inhibition of lipolysis. Moreover, obesity in
transgenic mice ubiquitously expressing agouti under the control of the �-actin promoter
was markedly attenuated by 4-wk treatment of a Ca2+- channel antagonist (nifedipine)
(20).
More recently, we reported that la.,25-(0H)2-D3 stimulates adipocyte Ca2+ influx via
the mVDR, resulting in a similar Ca2+ -mediated modulation of adipocyte lipid
metabolism (6, 21). la, 25-(0H)i-D3 also exerts an inhibitory effect on adipocyte UCP2
mRNA and protein levels via the nVDR, independent of its effects on Ca2+ influx (22).
Furthermore, we reported that feeding high calcium diets (non-fat dry milk) results in
decreased adipocyte [Ca2+]i, increased thermogenesis, and attenuation of adipocyte lipid
accretion and weight/fat gain in ad libitum fed mice and marked acceleration of
weight/fat loss secondary to caloric restriction (6, 9, 10). Accordingly, we proposed that
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suppressing la,25-(0H)i-D3 levels by increasing dietary calcium would suppress
adipocyte [ Ca2+]i, up-regulate UCP2, and consequently inhibit lipogenesis, stimulate
lipolysis, increase thermogenesis and decrease metabolic efficiency, thereby exerting an
anti-obesity effect.
Consistent with the animal observations, clinical and epidemiological observations
support these findings (6, 8,1 4). Epidemiologically, the effect of calcium intake on body
fat in humans was examined in the NHANES III data set (6). After controlling for energy
intake and energy expenditure, a strong inverse relationship was noted between calcium
intake and body fat in both women and men. The odds ratio of being in the highest
quartile of body fat was markedly reduced from 1 .00 for the first quartile of calcium
intake to 0.75, 0.40, and 0.1 6 for the second, third, and fourth quartiles of calcium intake,
respectively.
Collectively, dietary calcium may exert its anti-obesity effect for humans through the
mechanism we proposed above, and further investigation is needed to confirm this.
Notably, dairy sources of calcium exerted substantially greater effects in acceleration of
weight/fat loss secondary to caloric restriction compared to the same levels of calcium in
the form of calcium carbonate supplement (6, 9) although the additional component(s) of
dairy products responsible for this difference is not yet known. Moreover, the only dairy
product systematically tested in this manner has been non-fat dry milk (6, 9), and it is not
clear whether other forms of dairy products will exert comparable or greater weight-loss
effects secondary to caloric restriction. Accordingly, the present study was conducted to
determine the efficacy of a fermented dairy product, yogurt, presented either unflavored
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or strawberry-flavored, compared to calcium carbonate, in acceleration of weight and fat
loss secondary to caloric restriction in aP2-agouti transgenic mice.
III. Materials and Methods
A. Animals and diets
aP2-agouti transgenic mice from our breeding colony were used as an animal model
for dietary calcium modulation of adiposity in vivo. These transgenic mice express
normal agouti protein specifically in adipose tissue under the control of the adipose
tissue-specific fatty acid binding protein aP2 promoter (23), similar to the adipocyte
specific agouti expression in humans, and exhibit a normal pattern of leptin expression
and activity, similar to that found in humans. These mice are useful model for diet
induced obesity in that they are not obese on standard chow but are susceptible to diet
induced obesity (6, 9, 24).
This study was divided into two 6-wk stages. In the first 6-wk stage, fifty 28-wk-old
male aP2-agouti transgenic mice weighing 37.4 ± 3.7g (mean ± SE) were placed on a
modified AIN-93G basal diet with sub-optimal calcium (0.4%), sucrose as the sole
carbohydrate source, and fat increased to 25% of energy with lard. In the second 6-wk
stage, these diet-induced obese transgenic mice were randomly assigned to five groups of
ten animals in each group. One group continued ad libitum on the same low-calcium
(0.4%) basal diet with no further modifications, while the other four groups were
maintained with energy intake restricted to 70% of that found in the ad lib fed group, as
follows: ( 1 ) a basal restriction group was placed on the basal low-calcium (0.4%) diet; (2)
a plain yogurt-fed restriction group received the basal diet with --34% protein replaced by
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spray dried plain yogurt (Yoplait, General Mills, Inc., Minneapolis, MN) to bring the
calcium content of the diet to 1.2%. The carbohydrate and fat content of the diet were
adjusted to compensate for contributions from the yogurt, but no adJµstments were made
to the micronutrient content of the diet; (3) a strawberry-flavored yogurt-fed restriction
group, which received the basal diet with --34% of protein replaced by spray dried
strawberry-flavored yogurt (Yoplait, General Mills, Inc., Minneapolis, MN) to increase
dietary calcium to 1.2%, with carbohydrate and fat adjustments as described above; and
(4) a calcium carbonate restriction group, which received the basal diet supplemented
with calcium carbonate to increase calcium content to 1.2%. Diet was administered and
weighed daily, and body weight was monitored twice a week.
At the end of the second stage, all mice were sacrificed under anesthesia with a
pentobarbital (100 mg/kg body weight)/phenytoin (12.Smg/kg) mixture (Abbott
Laboratory, North Chicago, IL). Blood was collected via cardiac puncture for insulin
measurement. Fat pads (abdominal, epididymal, perirenal and subscapular),
gastrocnemius and soleus muscle were dissected and weighed immediately. The perirenal
fat pads were utilized immediately for baseline and isoproterenol-stimulated lipolysis, as
described below. Half of the abdominal fat pad from each animal was homogenized
immediately and then stored at -80°C for fatty acid synthase (FAS) activity assay. The
other half of the abdominal fat pad was frozen in liquid nitrogen immediately and stored
at -80° C for assessment of FAS and uncoupling protein 2 (UCP2) mRNA expression.

89

B. Blood glucose, insulin and core temperature measurements
Blood glucose was measured using the FastTake Blood Glucose Meter (Lifescan,
Inc.) weekly with blood taken from the tail vein. Serum insulin level was measured via
radioimmunoassay using mouse/rat insulin RIA kits (Linco Research, Inc., St. Charles,
MO). Core temperature was used as an indirect metabolic index to determine whether
dietary calcium regulates energy metabolism associated with increased thermogenesis, an
important contribution to energy expenditure. Temperature was measured via a
thermocouple (Columbus Instruments, Columbus, Ohio) weekly. The probe was inserted
a constant distance (1.8cm) into the rectum of each mouse. After stabilization (10s), the
temperature was recorded every 5 s for 30 s (6, 9, 20). All core temperature
measurements were performed weekly between 8 :00 and 9:30 A.M.

C. Mouse adipocyte intracellular Ca2+ ([Ca2+]J measurement
[Ca2+]i in isolated mouse adipocytes was measured by using a fura-2 dual wavelength
fluorescence imaging system (Intracellular Imaging, Inc.) (9). Briefly, mouse abdominal,
epididymal, perirenal and subscapular adipose tissues were first washed several times
with KRB buffer containing the following components (in mmol/L): NaCl 129, NaHC03
5, KCl 4.8, KH2P04 1.2, CaCh 2.0, MgS04 1.2, Glucose 5, HEPES 20, and bovine
serum albumin (BSA) 0.5%. They were then minced into small pieces, and digested with
0.8 mg/ml type I collagenase in a shaking water bath at 37°C for 1 hr. Adipocytes were
filtered through sterile 500-µm nylon mesh, rinsed several times with KRB buffer and
resuspended in KRB buffer. Adipocytes were then loaded with fura-2 acetoxymethyl
ester (AM) (10 µmol /L) (Sigma, St.Louis, MO) in the same buffer and incubated in a
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shaking water bath at 37°C in the dark for another 1 hr. Finally, adipocytes were rinsed
with KRB buffer three times to remove extracellular dye, and post-incubated at room
temperature for an additional 30 mins to ensure complete hydrolysis of cytoplasmic fura2 AM. A thin layer of adipocytes was plated in 35 mm dishes with glass coverslips
(P35GC-0-14-C, MatTek Corporation, Ashland, Mass.). The dishes with dye-loaded cells
were mounted on the stage of Nikon TMS-F fluorescence inverted microscope with a
Cohu 4915 CCD camera. Fluorescent images were captured alternatively at excitation
wavelength of 340 nm and 380 nm with an emission wavelength of 520nm. [Ca2+]i was
calculated by using a ratio equation (25).

D. Lipolysis assay
Immediately after the dissection, perirenal adipose tissue was incubated with KRB
buffer for 2 hrs either in the presence or absence of isoproterenol (lOOnM) in 37°C
incubator with 5% CO2 • Glycerol released into the KRB medium was determined as an
indicator of lipolysis by using a one-step enzymatic fluorometric method (26). Glycerol
release data was DNA corrected using CyQuant Cell Proliferation Assay Kit (Molecular
Probes, Eugene, OR.)

E. Fatty acid synthase (FAS) activity assay
FAS activity was determined spectrophotometrically in crude cytosolic extracts of
mouse adipose tissue. Mouse abdominal fat pads were homogenized in 250 mmol/L
sucrose solution containing 1 mmol/L ethylenediamine-tetraacticacid (EDTA), 1 mmol/L
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dithiothreitol (DTT), and lOOµmoVL phenylmethylsulfonyl Fluoride (PMSF) (PH7.4).
Homogenate was centrifuged at 14,000 rpm for 1 hr at 4°C, and the infranatant was used
for measuring oxidation rate of NADPH started by the addition of malonyl CoA (6, 9,
18, 20). FAS activity data was DNA corrected as described in lipolysis assay.

F. Northern blot analysis
Northern blot analysis was conducted as previously described (6, 9). Total celluar
RNA from mouse abdominal adipose tissue was extracted by using cesium chloride
(CsCh) density gradient centrifugation, run in 1% agarose gel, and transferred to nylon
membrane (New England Nuclear, Boston, Mass.). The membrane was hybridized with
mouse FAS or UCP-2 cDNA probes that were radiolabeled by using a random primer
method. Unbound probe was removed by rinsing the membrane with 2XSSC/O. l %SDS
for 30 min at room temperature and O. lXSSC/0.1%SDS for 45 min at 55°C. Finally,
membranes were exposed to X-ray film (New England Nuclear) at -80°C, and
autoradiograghs were quantitated densitometrically. All membranes were stripped and re
probed with 18S rRNA as loading control.

G. Statistical analysis
All data are expressed as mean ± SE. Data were analyzed for statistical significance
via one-way analysis of variance (ANOVA), followed by separation of si gnificantly
different group means via the least si gnificant difference (LSD) test using SPSS (v.10.0).
A p value < 0.05 is considered significant.
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IV. Results

Administration of the basal low-calcium (0.4%)/ high-fat/ high-sucrose diet to mature
aP2-agouti transgenic mice for six weeks resulted in a body weight gain of 1 7%
(37.4±0.5g vs. 43.9±0.6 g, n=50, p< 0.001 ; Fig.4), demonstrating the obesity promoting
effect of this diet.
Six weeks of energy restriction resulted in a body weight loss of 25%, compared to
the ad lib basal group, which exhibited a slight (3%) further increase in body weight
[p<0.001 ; Fig. 5 (upper panel)] . Moreover, a significantly greater weight reduction of
3 1 % was observed in the calcium carbonate (CaC0 3) group [p<0.001 vs. restriction
J,asal; Fig. 5 (upper panel)], while the two yogurt groups exhibited a significantly greater
40% weight loss [p<0.01 vs. restriction CaC0 3 ; Fig. 5 (upper panel)] . Similarly, energy
restriction caused a 29% decrease in total fat pad mass [p<0.001 vs. ad lib basal; Fig .. 5
(middle panel)], while markedly greater reductions of 49%, 72% and 76% were found
with calcium carbonate, strawberry yogurt and plain yogurt diet, respectively [p<0.001
vs. restriction basal; Fig. 5 (middle panel)] . The two yogurt groups exhibited significantly
greater !eductions in fat mass than the calcium carbonate group (p<0.00 1). Interestingly,
we also found that mice fed the two yogurt diets had significantly higher gastrocnemius
muscle weight, adjusted for body weight, compared to the other groups [p<0.05 ; Fig.5
(lower panel)].
Energy restriction caused only 1 7% decrease in adipocyte [Ca2Ji (1 70±6 nM vs.
206±27 nM, p<0.05 vs. ad lib basal; Fig. 6), whereas all three high calcium diets caused
substantial (69%-72%) decreases in [Ca2+]i (p<0.001 vs. restriction basal; Fig. 6). Figure
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Figure 4. Effect of 6-week administration of basal low-calcium (0.4%) /
high fat I high sucrose diet on body weight in aP2-agouti transgenic mice.
Diet and animal administration was conducted as described in Materials and
Methods. Data are expressed as mean ± SE (n=50).
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Figure 5. Effect of 6-wk administration of high calcium diets (1 .2%) on body weight change
(upper panel), fat pad mass (middle panel) and gastrocnemius muscle weight (lower panel) in
energy-restricted (70% of ad lib) aP2-agouti transgenic mice. Diet and animal administration
was conducted as described in Materials and Methods. Data are expressed as mean ± SE
(n= lO/group).
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adipocyte [Ca2+]i in energy restricted (70% of ad lib) aP2-agouti transgenic
mice. Diet and animal administration was conducted as -described in Materials
and Methods. Data are expressed as mean ± SE (n= l O/group)
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7 demonstrates that energy restriction alone did not affect adipocyte basal (upper panel)
or isoproterenol-stimulated lipolysis (middle panel). However, the calcium carbonate diet
caused 78% and 8 1 % stimulation on basal and isoproterenol-stimulated lipolysis,
respectively (p<0.05 vs. restriction basal), which were further stimulated in the two
yogurt diet groups (p<0.05 vs. restriction CaC03). Figure 7 lower panel demonstrates that
energy restriction caused a 59% decrease in adipocyte FAS mRNA expression (p<0.001
vs. ad lib basal), while markedly greater reductions (84%-89%) were found with all three
high calcium diets (p<0.05 vs. restriction basal).
After 6-wk dietary treatment, both the plain yogurt and calcium carbonate groups
exhibited an increase in core temperature of 0.71 and 0.76°C, respectively (p<0.05 vs. ad
lib basal, Table 2). Figure 8 shows all three high calcium diets up-regulated white adipose

tissue UCP2 mRNA expression by an average of 66% (p<0.0 1 ), while energy restriction
alone had no significant effect.
Six-wk feeding of the basal high fat/high sucrose/low calcium obesity-promoting diet
exerted a diabetogenic effect with an average high blood glucose level of 1 32 ± 5 mg/dl
and a corresponding degree of compensatory hyperinsulinemia. Energy restriction alone
lowered plasma glucose level by 22% (139 ± 6 mg/dl vs. 109 ± 4 mg/dl, p<0.05, Table 3)
and dramatically reduced insulin level by 74% (4.39 ± 0.84 ng/ml vs. 1 . 1 4 ± 0.3 ng/ml,
p<0.00 1 , Table 4), and subsequently reduced plasma insulin to glucose ratio, improving
insulin sensitivity. All the three high calcium diets did not further significantly reduced
these parameters.
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Table 2. Effect of high calcium diets (1 .2%) on core temperature change in energy
restricted (70% of ad lib) aP2-agouti transgenic mice. Diet and animal administration

was conducted as described in Materials and Methods. Data are expressed as
mean ± SE (n= lO/group). ap<0.05 vs. ad lib Basal.

Groups
(n= l O)

Before
(° C)

After
(° C)

Change
(OC)

ad lib Basal

36.7±0.30

36.41±0.22

-0.29

Restriction
Basal

36. 1 9±0.29

36.66±0. 1 5

+0.47

Plain Yogurt

35.93±0.30

36.64±0. 12

+0.7 t a

Strawberry
yogurt

36.3 5±0.35

36.75±0.09

+0.40

Calcium
Carbonate

36.33±0.36

37.09±0.09

+0.76 a
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Figure 8. Effect of 6-wk administration of high calcium diets (1 .2%) on UCP2
mRNA expression in energy-restricted (70% of ad lib) aP2-agouti transgenic
mice. Diet and animal administration was conducted as described in Materials
and Methods. Data was expressed as mean ± SE {n= lO/group).
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Table 3. Effect of 6-week energy restriction (70% of ad lib) and high calcium diets (1 .2%)
on blood glucose level change in aP2-agouti transgenic mice. Diet and animal administration
was conducted as described in Materials and Methods. Data are expressed as mean ± SE
(n= lO/group). a p<0.05 vs. ad lib Basal.

Groups
(n= l O)

Before
(mg/dl)

After
(mg/dl)

Change
(mg/dl)

ad lib Basal

129±7

1 26±5

-3

Restriction Basal

1 39±6

1 09±4

Plain Yogurt

1 29±5

93+6

- 36

Strawberry
yogurt

1 38±6

1 05±8

_ 33 a

Calcium
Carbonate

1 25±3

99±5

- 26

-

3oa
a

a
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Table 4. Effects of 6-week energy restriction (70% of ad lib) and high calcium diets ( 1 .2%)
on serum insulin level, blood glucose ievel and insulin / glucose ratio in aP2-agouti
transgenic mice. Diet and animal administration was conducted as described in Materials
and Methods. Data are expressed as mean ± SE (n= l O/group).
a p<0.001 vs. ad lib Basal
h p<0.05 vs. ad lib Basal

Groups
(n= lO)

Serum insulin
(ng/ml)

Glucose
(mg/di)

Plain
yogurt

Strawberry

Basal

Restriction
Basal

yogurt

Calcium
Carbonate

4.39 ± 0.84

1.1 4 ± 0.3•

0.44 ± 0.12•

1.25 ± 0.37•

1.13 ± 0.44•

126 ± 5

109 ± 4b

93 ± 6b

105 ± 8b

ad lib

99 ± 5b

i

Insulin/Glucose

0.010

0.035 ± 0.007

I
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± 0.003•

0.005 ± 0.001 •

0.012± 0.004•

I

0.011±0.004•

V. Discussion

Data presented in this study demonstrate that high calcium diets with calcium sources
from plain yogurt, strawberry-flavored yogurt and calcium carbonate supplement
suppress adipocyte [Ca2+ ]i, up-regulate UCP2, inhibit lipogenesis, stimulate lipolysis,
increase thermogenesis and decrease metabolic efficiency, thereby accelerating
weight/fat loss during caloric restriction in aP2-agouti transgenic mice. Notably, yogurt
exerted a significantly greater effect than calcium carbonate. These findings support and
extend our previous observations using non-fat dry milk in the same mouse model (9).
McCarron, in his evaluation of the relationship between blood pressure and nutrient
intake in the U. S. population in 1984, first noted a significant inverse relationship
between calcium intake and body weight (1). Since then, Metz et al. (2) and Bursey et al.
(3) reported that increasing dietary calcium reduced body fat composition and body
weight in spontaneously hypertensive rats (Wistar-Kyoto rats) and in both lean and
obese Zucker rats. However, they were unable to demonstrate the mechanism involved in
this adiposity modulation. Although some investigators have attributed the effect of
dietary calcium on lipid metabolism to potential inhibition of dietary fat absorption or
fecal fat loss, significant fecal energy loss does not result from moderate increases in
dietary calcium (27-29). In a randomized controlled clinical trial of reducing diets in
adult outpatients, those maintained on a milk-based diets for 16 wks had greater weight
loss (7.0 vs. 1.7 kg) than patients maintained on a conventional hypocaloric diet that was
isocaloric to the milk-based diet (5). The investigators proposed that greater compliance
with the novel milk-based diet may have contributed to the greater weight loss. However,
the present study, combined with our previous studies (6, 9), indicates that intracellular
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Ca2+ concentration ([Ca2+] i) plays a regulatory role in this adiposity modulation exerted
by dietary calcium. That is, high calcium diets suppress adipocytes [Ca2+]i by suppressing
circulating calcitrophic hormone la, 25-(0H)2-D3 levels, and consequently inhibit
lipogenesis and stimulate lipolysis, thereby exerting an anti-obesity effect.
Several lines of evidence demonstrated that circulating la.,25-(0H)2-D3 level is
increased in obese humans (30, 31). It has been previously demonstrated that increasing
dietary calcium suppress circulating la.,25-(0H)2 -D3 levels in multiple studies (32, 33).
Moreover, la.,25-(0H)2 -D3 has been shown to stimulate increases in [Ca2+]i via
membrane vitamin D receptor (mVDR) in both vascular smooth muscle cells (34) and
pancreatic �-cells (35) and to play a role in the development of hypertension and
hyperinsulinemia, respectively. Importantly, we recently reported that la.,25-(0H)2-D3
also acted on human adipocytes via mVDR to cause a sustained increase in [Ca2+] i and a
corresponding marked inhibition of lipolysis and stimulation of lipogenesis (6, 36). Thus,
high calcium diets would suppress circulating la.,25-(0H)2-D3 level, which would
subsequently suppress adipocyte [Ca2+]i. Indeed, our data show that all three high calcium
diets induced substantial decreases in adipocyte [Ca2+] i of energy-restricted mice,
compared to energy restriction alone.
Draznin et al. first reported that obese patients exhibited an elevation in basal
adipocyte [Ca2+] i (37). The physiological consequence of this elevation in adipocyte
[Ca2+]i was addressed by our previous studies of the mechanism of action of agouti gene
in obesity and insulin resistance. In particular, agouti protein caused dose-responsive
increases in Ca2+ influx and steady-state [Ca2+]i in a variety of cell types, including both
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murine and human adipocytes (17). Agouti protein also stimulates the expression and
activity of fatty acid synthase (FAS), a key enzyme in de novo lipogenesis, and inhibits
basal and agonist-stimulated lipolysis in both human and murine adipocytes ( 1 8, 1 9).
Moreover, this agouti modulation of lipid metabolism is fully mimicked by Ca2+ channel
agonists and inhibited by Ca2+ channel antagonists ( 1 8, 1 9). Indeed, Ca2+-channel
blockade has been shown to reduce body weight and fat pad mass effectively in several
animal models. Ca2+- channel antagonists, such as nifedipine, verapamil and felodipine,
caused decreases in body weight and fat pad mass in obese SHHF/Mcc-facp rats (3 8, 39).
Similarly, we previously reported that treatment of transgenic mice ubiquitously
expressing agouti under the control of the J3-actin promoter with a Ca2+- channel
antagonist (nifedipine) for 4 weeks resulted in significant decreases in adipocyte
lipogenesis and an 1 8% reduction in fat pad mass (20). Therefore, increasing [Ca2+]i
appears to promote triglyceride storage in adipocytes by coordinately stimulating
lipogenesis and suppressing lipolysis.
In present study, reduction of [Ca2+]i was achieved by feeding high calcium diets. Our
data show that high calcium diets caused marked inhibition of FAS mRNA expression.
FAS is known to be regulated primarily at transcription level by nutrients and hormones
(40). Moreover, both basal and isoproterenol-stimulated lipolysis were enhanced with
high calcium diets while energy restriction alone was without effect on lipolysis.
Correspondingly, total fat pad mass and body weight reflected these changes, with a 45%
augmentation in fat loss on the two yogurt diets compared to that on the low calcium diet
secondary to caloric restriction (p<0.001). Calcium carbonate supplementation produced
an intermediate effect, with a 28% augmentation in fat loss compared to that on the low
. 1 05

calcium diet secondary to caloric restriction (p<0.001). Interestingly, energy-restricted
mice fed on two yogurt diets had significantly higher gastrocnemics muscle weight,
adjusted by body weight, than those maintained on ad lib basal low calcium diet. Energy
restriction alone and the calcium carbonate supplement diet had no effect on
gastrocnemics muscle weight.
Taken together, these data demonstrate that dietary calcium-induced downregulation
of adipocyte [Ca2+]i may be associated with decreased adiposity via coordinate
stimulation of lipolysis and inhibition of lipogenesis. Notably, yogurt exerts a greater
effect on lipid metabolism and corresponding body weight and adipose tissue mass
reduction compared with a comparable quantity of calcium in the form of calcium
carbonate. The reason for this difference is not yet apparent although it is consistent with
our previous observations (6, 9). It is interesting that all three high calcium diets exerted
+

comparable effects in lowering [ Ca2 ]i despite the marked differences in the effects of
elemental versus yogurt calcium on adipose tissue mass reduction. This finding suggests
that other components of yogurt may act via a [Ca2+]i-independent system to further
reduce adiposity and facilitate nutrient partitioning from adipose tissue to skeletal muscle.
Dairy proteins have been reported to contain significant angiotensin-I converting enzyme
(ACE) inhibitory activity (4 1 , 42), which caused decreased conversion of angiotension II
(All) from angiotension I (AI). All not only increases blood pressure but also exerts an
insulin-like effect in adipocytes and acts as a lipogenic hormone to increase FAS enzyme
activity and mRNA content, subsequently increasing fatty acid and triglyceride synthesis
(43). Indeed, inhibition of the rennin-angiotensin system mildly attenuates obesity in
rodents, and limited clinical observations support this concept in hypertensive patients
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treated with ACE inhibitors (44). However, further investigations are necessary to
identify the additional component(s) of dairy products that contribute to the greater effect
on energy metabolism than calcium carbonate supplement.
Consistent with our previous study (9), high calcium diets not only modulate lipid
metabolism involved in lipogenesis and lipolysis, but also cause a higher core
temperature and an increased white adipose tissue UCP2 mRNA expression. In fact, we
have also previously observed an increased core temperature in transgenic mice
ubiquitously expressing agouti under the control of the J3-actin promoter after mice were
treated with Ca2+ channel antagonist nifedipine (20). The contribution of thermogenesis
to anti-obesity action of Ca2+ channel blockade has been addressed in previous studies
(45, 46), but the mechanism remains controversial. Some investigators have attributed the
thermogenic effect of Ca2+ channel blockade to the increased function of brown adipose
tissue (45, 46). The present study, combined with our previous study (9), suggest that up
regulation of UCP2 expression may be responsible for thermogenesis since UCP2 has
been shown to stimulate mitochondrial proton leak and therefore exhibit a potential role
in thermogenesis, energy metabolism and obesity (47, 48). This concept was confirmed
by our recent study demonstrating that la, 25-(0H) 2-D3 exerted an inhibitory effect on
adipocyte UCP2 mRNA and protein levels via the nVDR, independent of its effects on
Ca2+ influx via the mVDR (22). Thus, suppression of 1a, 25-(0H)2 -D3 with high calcium
diets and consequent up-regulation of UCP2 via genomic action may contribute to our
observations of increased thermogenesis in mice fed with high calcium diets. This effect,
coupled with decreased lipogenesis and increased lipolysis secondary to decreased [Ca2+]i
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mediated by nongenomic action may contribute to an anti-obesity effect of dietary
calcium.
ad lib feeding of the basal low-calcium diet caused sustained hyperinsulinemia. Data

from the present study demonstrate that energy restriction per se reduced the plasma
insulin levels and that increasing dietary calcium did not further reduce insulin but
nonetheless exerted potent effects on body weight loss and fat pad mass reduction. Thus,
the effects of dietary calcium on accelerating weight/fat loss are not due to reduced
insulin levels and instead are likely to result from the observed suppression of adipocyte
[Ca2+]i and modulation of adipocyte lipid metabolism.
Recently, accumulating human studies strongly support the anti-obesity effect of
dietary calcium (7, 8, 11-15). Davis et al. (8) have conducted a series of calcium
intervention studies in women designed with the bone mass the original outcome
variable, and have recently re-evaluated these data with body weight and body fat the
outcome variable. The re-analysis reveals a consistent negative association between
calcium intake and body weight for all age groups (3rd, 5th and 8th decades of life), and
an odds ratio for being oveiweight of 2.25 for young women in the lower half versus the
upper half of calcium intake. Data from the randomized controlled trial demonstrated a
calcium treatment effect of 0.325 kg weight loss per year over four years with no
intentional change in caloric intake; overall, the relationships derived from this re
analysis indicate that a calcium intake increase of 1000 mg/day is associated with an 8 kg
reduction in body weight. A similar beneficial effect of dietary calcium on body fat mass
reduction has been demonstrated in growing children as well. Carruth and Skinner
reported that higher longitudinal intakes of calcium and servings of dairy products were
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associated with lower body fat in preschool children (12). Finally, our recent clinical trial
on obese subjects demonstrates that increasing dietary calcium significantly augments
weight and fat loss secondary to caloric restriction and increases the percentage of fat lost
from the trunk region. Moreover, dairy products exert a substantially greater effect on
both fat loss and fat distribution compared to an equivalent amount of supplemental
calcium (14).
In summary, high calcium diets with calcium sources from plain yogurt, strawberry
flavored yogurt and calcium carbonate supplement exert potent effects in enhancing
reduction of body weight and fat pad mass in energy-restricted aP2-agouti transgenic
mice by suppressing adipocyte [Ca2+]i, up-regulating UCP2 in adipocytes, and
consequently inhibiting lipogenesis, stimulating lipolysis, increasing thermogenesis and
decreasing metabolic efficiency. Notably, yogurt exerted a significantly greater effect
than calcium in the form of calcium carbonate. Thus, fermented dairy products may be
useful for further development of effective dietary intervention in obesity.
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PART 4
SUMMARY AND CONCLUSIONS
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The objective of this thesis research was to extend our previous observations of anti
obesity role of dietary calcium by determining the efficacy of a fermented dairy product,
yogurt, presented either unflavored or strawberry-flavored, compared to calcium ·
carbonate, in accelerating weight and fat loss secondary to caloric restriction in aP2agouti transgenic mice.
This thesis has demonstrated that high calcium diets with calcium sources from plain
yogurt, strawberry-flavored yogurt and calcium carbonate supplement suppress adipocyte
[Ca2+]i and up-regulate UCP2 via suppression of la,25-(0H)2-D3, and thereby reduce
energy storage via coordinately stimulating lipolysis and inhibiting lipogenesis, decrease
metabolic efficiency via increasing thermogenesis, and accelerate body weight/fat loss
during energy restriction, with significantly greater effects exerted by yogurt than by
supplemental calcium. These findings extend our previous observations using non-fat dry
milk in the same mouse model and further confirm the mechanisms underlying this
dietary calcium modulation of adiposity we proposed earlier. At the same time,
accumulating human studies also strongly support an anti-obesity role for dietary
calcium. In conclusion, dietary calcium, especially dairy calcium, may be effective
dietary regimen for the treatment of obesity.
Further investigations are necessary to identify the additional component( s) of dairy
products that contribute to the greater effect on energy metabolism than calcium
carbonate supplement.
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